curr_10q.htm

0001477932-17-003933.txt : 20170814 0001477932-17-003933.hdr.sgml : 20170814 20170814154026 ACCESSION NUMBER: 0001477932-17-003933 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170814 DATE AS OF CHANGE: 20170814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cure Pharmaceutical Holding Corp. CENTRAL INDEX KEY: 0001643301 STANDARD INDUSTRIAL CLASSIFICATION: PLASTICS, FOIL & COATED PAPER BAGS [2673] IRS NUMBER: 371765151 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-204857 FILM NUMBER: 171029803 BUSINESS ADDRESS: STREET 1: 1620 BEACON PLACE CITY: OXNARD STATE: CA ZIP: 93033 BUSINESS PHONE: 805-824-0410 MAIL ADDRESS: STREET 1: 1620 BEACON PLACE CITY: OXNARD STATE: CA ZIP: 93033 FORMER COMPANY: FORMER CONFORMED NAME: Makkanotti Group Corp. DATE OF NAME CHANGE: 20150526 10-Q 1 curr_10q.htm FORM 10-Q curr_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2017

¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from __________ to __________

Commission file number 333-204857

CURE PHARMACEUTICAL HOLDING CORP.

(Exact name of registrant as specified in its charter)

Nevada

2673

37-1765151

(State or other jurisdiction

of incorporation or organization)

(Primary Standard Industrial

Classification Number)

(IRS Employer

Identification Number)

1620 Beacon Place, Oxnard, California 93033

(Address of principal executive offices)

(805) 824-0410

(Issuer’s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”,“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x
		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

On August 10, 2017, we had 23,751,252 shares of common stock, par value $0.001 per share (the “Common Stock”) issued and outstanding.

TABLE OF CONTENTS

		Page

PART I. FINANCIAL INFORMATION:

Item 1.	Unaudited Condensed Consolidated Financial Statements		3

	Condensed Consolidated Balance Sheets as of June 30, 2017 (Unaudited) and December 31, 2016		3

	Unaudited Condensed Consolidated Statements of Operations for the three and six month periods ended June 30, 2017 and 2016		4

	Unaudited Condensed Consolidated Statements of Cash Flows for the six month periods ended June 30, 2017 and 2016		5

	Notes to the Unaudited Condensed Consolidated Financial Statements		6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		17

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		21

Item 4.	Controls and Procedures		22

PART II. OTHER INFORMATION:

Item 1.	Legal Proceedings		23

Item 1A.	Risk Factors		23

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		23

Item 3.	Defaults Upon Senior Securities		23

Item 4.	Mine Safety Disclosure		23

Item 5.	Other Information		23

Item 6.	Exhibits		24

	Signatures		25

2

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

CURE PHARMACEUTICAL HOLDING CORP.

Condensed Consolidated Balance Sheets

	June 30, 2017			December 31, 2016
	(Unaudited)
Assets
Current assets:
Cash	$	277,961		$	1,106,142
Accounts receivable		13,443			7,049
Inventory		103,989			81,285
Prepaid expenses and other assets		1,695,930			223,879
Total current assets		2,091,323			1,418,355
Property and equipment, net		324,651			370,648
Intellectual property and patents, net		889,345			894,510
Other assets		133,878			151,579
Total assets	$	3,439,197		$	2,835,092

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	416,736		$	265,386
Accrued expenses		36,441			26,305
Loan payable		11,460			33,277
Note payable, net of unamortized discount		695,250			50,000
Capital lease payable		3,234			9,453
Convertible promissory notes, net of unamortized discount		100,937			-
Derivative liability		412,777			-
Deferred revenue		192,600			173,618
Total current liabilities		1,869,435			558,039
License Fees		560,000			560,000
Total liabilities		2,429,435			1,118,039

Stockholders’ equity:
Common stock: $0.001 par value; authorized 75,000,000 shares; 23,751,252 and 23,336,673 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively		23,752			23,337
Additional paid-in capital		16,866,149			12,412,430
Accumulated deficit		(15,880,139	)		(10,718,714	)
Total stockholders’ equity		1,009,762			1,717,053
Total liabilities and stockholders’ equity	$	3,439,197		$	2,835,092

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

Table of Contents

CURE PHARMACEUTICAL HOLDING CORP.

Condensed Consolidated Statements of Operations (Unaudited)

For the Three and Six Months Ended June 30, 2017 and 2016

Three Months Ended June 30,

Six Months Ended June 30,

2017

2016

2017

2016

Revenue

Net product sales

$ 32,073

$ 14,151

$ 59,570

$ 42,662

Consulting research & development income

-

-

4,448

-

Shipping and other sales

6,812

3,000

6,812

3,098

Total revenues

38,885

17,151

70,830

45,760

Cost of goods sold

39,598

10,579

75,148

37,744

Gross profit (loss)

(713 )

6,572

(4,318 )

8,016

Research and development expenses

205,648

171,447

425,268

298,799

Selling, general and administrative expenses

2,194,950

304,669

4,597,497

596,605

Total costs and expenses

2,400,598

476,116

5,022,765

895,404

Net loss from operations

(2,401,311 )

(469,544 )

(5,027,083 )

(887,388 )

Other income (expense):

Interest income

1

45

5

412

Other income

8,571

8,571

17,142

17,142

Loss on disposal of PP&E

(12,351 )

-

(12,351 )

(3,323 )

Change in derivative liability

(42,545 )

-

(42,545 )

-

Other expense

(6,394 )

(88,491 )

(7,388 )

(100,634 )

Interest expense

(87,054 )

(47,603 )

(89,205 )

(99,321 )

Other income (expense)

(139,772 )

(127,478 )

(134,342 )

(185,724 )

Net loss before income taxes

(2,541,083 )

(597,022 )

(5,161,425 )

(1,073,112 )

Provision for income taxes

-

-

-

-

Net loss

$ (2,541,083 )

(597,022 )

$ (5,161,425 )

$ (1,073,112 )

Net loss per share, basic and diluted

$ (0.11 )

(0.09 )

$ (0.22 )

$ (0.16 )

Weighted average shares outstanding, basic and diluted

23,436,696

6,629,260

23,593,105

6,629,260

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Table of Contents

CURE PHARMACEUTICAL HOLDING CORP.

Condensed Consolidated Statements of Cash Flows (Unaudited)

For the Six Months Ended June 30, 2017 and 2016

	For the Six			For the Six
	Months Ended			Months Ended
	June 30, 2017			June 30, 2016

Cash flows from operating activities
Net loss	$	(5,161,425	)	$	(1,073,112	)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		98,161			75,394
Loss from joint venture		5,488			-
Loss on disposal of PP&E		12,351			3,323
Amortization of prepaid stock –based compensation		552,010			-
Amortization of loan discounts		82,933			-
Change in derivative liabilities		42,545			-
Warrants issued for services		2,717,620			-
Change in other assets and liabilities:
Restricted cash		-			(50,000	)
Accounts receivable		(6,394	)		1,679
Inventory		(22,704	)		12,975
Prepaid expenses and other assets		(594,061	)		(703,838	)
Other assets		17,213			8,858
Accounts payable		151,350			(265,682	)
Accrued expenses		10,136			46,823
Deferred revenue		18,982			(28,539	)
Net cash used in operating activities		(2,075,795	)		(1,972,119	)

Cash flows from investing activities
Advanced on note receivable		-			(18,290	)
Purchase in intangible assets		(16,555	)		(25,527	)
Payment to joint venture investment		(5,000	)		-
Acquisition of property and equipment, net		(42,795	)		(48,830	)
Net cash used in investing activities		(64,350	)		(92,647	)

Cash flows from financing activities
Proceeds from loan		1,340,000			4,371,963
Loan repayments		(21,817	)		(289,253	)
Capital lease payments		(6,219	)		(5,509	)
Net cash provided by financing activities		1,311,964			4,077,201

Net increase (decrease) in cash and cash equivalents		(828,181	)		2,012,435
Cash and cash equivalents, beginning of period		1,106,142			13,352
Cash and cash equivalents, end of period	$	277,961		$	2,025,787

Supplemental cash flow information
Cash paid for interest and income taxes:
Interest	$	2,967		$	28,892
Income taxes		-			-

Non-cash financing activities:
Common stock to be issued for prepaid expense	$	1,430,000		$	-
Loan discount relating to note payable		10,000			-
Loan discount relating to convertible promissory notes		676,746			-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

Table of Contents

CURE PHARMACEUTICAL HOLDING CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

(UNAUDITED)

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

Cure Pharmaceutical Holding Corp (the “Company”), formerly known as Makkanotti Group Corp, was incorporated in the State of Nevada on May 15, 2014. The Company was formed to engage in the business of manufacturing food paper bags in Nicosia, Cyprus. On November 7, 2016, the Company changed its name to Cure Pharmaceutical Holding Corp.

On November 7, 2016, the Company, in a reverse take-over transaction, acquired Cure Pharmaceutical Corporation (“Cure Pharmaceutical”), a specialty pharmaceutical and bioscience company based in California that specializes in drug delivery technologies, by executing a Share Exchange Agreement and Conversion Agreement (“Exchange Agreement”) by and among the Company and a holder of a majority of the issued and outstanding capital stock of the registrant prior to the closing (the “Majority Stockholder”), on the one hand, and Cure Pharmaceutical, a California corporation, all of the shareholders of Cure Pharmaceutical’s issued and outstanding share capital (the “Cure Pharm Shareholders”) and the holders of certain convertible promissory notes of Cure Pharmaceutical (“Cure Pharm Noteholders”), on the other hand. Hereinafter, this share exchange transaction is described as the “Share Exchange.” As a result of the Share Exchange, Cure Pharmaceutical became a wholly owned subsidiary of the Company, and the Cure Pharm Shareholders and Cure Pharm Noteholders became the controlling shareholders of the Company.

For accounting purposes, Cure Pharmaceutical shall be the surviving entity. The transaction is accounted for using the reverse acquisition method of accounting. As a result of the recapitalization and change in control, Cure Pharmaceutical is the acquiring entity in accordance with ASC 805, Business Combinations.

Cure Pharmaceutical Corporation is a specialty pharmaceutical and bioscience company with a focus in drug delivery technologies. Cure leverages novel drug delivery technologies to develop and commercialize new applications of proven therapeutics through Oral Thin Film (“OTF”) via our proprietary patented CureFilm™ Technology as well as through transdermal applications. Our micro encapsulation of drug actives in our CureFilm™ Technology allows for a higher volume of an active and if required, multiple actives to be produced on a single oral thin film strip.

The Company is focused on partnering with pharmaceutical and biotech companies seeking to deliver drug actives utilizing and benefitting from our proprietary OTF and transdermal applications and when preferable to take our own products from clinical process to commercialization. We are focused on both the human and veterinary prescription, OTC and nutraceutical markets. Cure represents the complete solution for OTF drug delivery therapeutics from inception to finished product utilizing our CGMP/FDA registered manufacturing facility and processes.

In July 2017 the Company, Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company dedicated to the development of cannabinoid-based drugs headquartered in Israel, and Assuta Medical Centers, Ltd., a medical services center located in Israel, entered into a nonbinding memorandum of understanding to collaborate to advance, research, develop and commercialize potential therapeutic products in the fields of personalized medicine and cannabinoids. The Company has not entered into any binding agreements or advanced any funds in connection with the foregoing.

The Company is still finalizing a research contract with Technion Research & Development Foundation Ltd. (“TRDF”) related to research regarding the effectiveness of certain cannabinoid strain extracts for specific genetic sub-types of cancer. On May 1, 2017, the Company paid $642,500 to initiate the research project with TRDF.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Basis of Presentation

The condensed consolidated financial statements include the accounts of Cure Pharmaceutical Holding Corp (“CPHC”) and its wholly-owned subsidiary, Cure Pharmaceutical Corporation (“Cure”), collectively referred to as (“Cure”, “we”, “us”, “our” or the “Company” All significant inter-company balances and transactions have been eliminated in consolidation. The Company’s film strip product represents the principal operations of the Company.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2017, and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2017 and 2016, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in Form 10-K for the fiscal period ended December 31, 2016 filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2017.

6

Table of Contents

CURE PHARMACEUTICAL HOLDING CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

(UNAUDITED)

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. These estimates and assumptions also affect the reported amounts of revenues, costs and expenses during the reporting period. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents. As of June 30, 2017 and December 31, 2016, the Company had no cash equivalents. At June 30, 2017 and December 31, 2016, the Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (“FDIC”) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions.

Investment in Associates

An associate is an entity over which the Company has significant influence through a joint venture. Significant influence is the power to participate in the financial and operating policy decisions of the investee but not control or joint control over those policies.

The results of assets and liabilities of associates are incorporated in the condensed consolidated financial statements using the equity method of accounting. Under the equity method, investments in associates are carried in the consolidated balance sheet at cost as adjusted for post-acquisition changes in the Company’s share of the net assets of the associate, less any impairment in the value of the investment. Losses of an associate in excess of the Company’s interest in that associate are not recognized. Additional losses are provided for, and a liability is recognized, only to the extent that the Company has incurred legal or constructive obligations or made payments on behalf of the associate.

Any excess of the cost of acquisition over the Company’s share of the net fair value of the identifiable assets, liabilities and contingent liabilities of the associate recognized at the date of acquisition is recognized as goodwill. The goodwill is included within the carrying amount of the investment.

On January 8, 2016, the Company received 50% ownership in Cure Innovations, Inc (“CI”). CI was created in 2015 by IncuBrands Studio, Inc (“IncuBrands”). The Company and IncuBrands each own 50% of the common stock of CI. The Company and IncuBrands entered into a Joint Venture agreement in 2013 to distribute several OTF products utilizing IncuBrands marketing and contacts in various industries as well as utilize the Company’s technology and capabilities of manufacturing OTF’s.

On December 6, 2016, the Company entered into a Joint Venture Agreement (“Joint Venture”) with Pace Wellness, Inc. (“Pace”) to jointly develop three Active Pharmaceutical Ingredients (“API”) within the nonprescription and/or Over-the-Counter (OTC) medicines specifically utilizing the Company’s patented and proprietary CureFilm™ Technology. The three API’s to be jointly developed are Diphenhydramine HCL, Omeprazole and a third API to be determined at a later date (“Products”). Pace shall be the exclusive global distributor of the Products under the Solves Strips® branding or other private or branded labels. All benefits, advantages, and liabilities derived from, or incurred in respect of the Joint Venture shall be borne by the parties in proportion of their respective participating interests of 50/50 equal interest.

Property and Equipment

The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred. Depreciation has been provided using the straight-line method on the following estimated useful lives:

Manufacturing equipment		5-7 Years
Computer and other equipment		3-7 Years
Leasehold Improvements		Lesser of useful life or the term of the lease

7

Table of Contents

CURE PHARMACEUTICAL HOLDING CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

(UNAUDITED)

Accounts Receivable

Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts.

Impairment of Long-Lived Assets

Long-lived assets include equipment and intangible assets other than those with indefinite lives. We assess the carrying value of our long-lived asset groups when indicators of impairment exist and recognize an impairment loss when the carrying amount of a long-lived asset is not recoverable when compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset.

Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the fair value of the asset (or asset group), typically a discounted cash flow analysis, and an impairment charge is recorded for the excess of carrying value over fair value. There were no impairments on our long-lived assets during the three and six month periods ended June 30, 2017 and 2016.

Revenue Recognition

The Company recognizes revenue in accordance with the FASB ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Company believes that these criteria are satisfied upon shipment from our facility. Freight billed to customers is presented as revenues, and the related freight costs are presented as cost of goods sold. Deferred revenue is recognized when earned and all significant obligations have been satisfied.

Advertising Expense

The Company expenses marketing, promotions and advertising costs as incurred. Such costs are included in general and administrative expense in the accompanying statements of operations. The Company recorded advertising costs of $68,893 and $95,226, for the three and six month periods ended June 30, 2017, respectively, and none for the three and six month periods ended June 30, 2016.

Research and Development

Costs incurred in connection with the development of new products and processes are charged to research and development expenses as incurred.

Income Taxes

The Company utilizes FASB ASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the net operating loss carry forward prior to its expiration.

8

Table of Contents

CURE PHARMACEUTICAL HOLDING CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

(UNAUDITED)

Stock-Based Compensation

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date.

Fair Value Measurements

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

The estimated fair value of certain financial instruments, including cash and cash equivalents are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

The Company has assets or liabilities valued at fair value on a recurring basis for the six months ended June 30, 2017. The Company did not have assets or liabilities valued at fair value on a recurring basis for the year ended December 31, 2016.

Basic and diluted loss per share

Basic loss per share is computed by dividing the net loss to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the net loss for the period by the weighted average number of common and dilutive common equivalent shares outstanding during the period. Common equivalent shares, which consist of stock options, warrants, and convertible notes payable, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.

Going Concern

The Company’s financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit at June 30, 2017 of $15,880,139. The Company had a working capital of $221,888 as of June 30, 2017. These factors raise substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance of the financial statements. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. The Company is continually analyzing its current costs and is attempting to make additional cost reductions where possible. We expect that we will continue to generate losses from operations throughout 2017.

9

Table of Contents

CURE PHARMACEUTICAL HOLDING CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

(UNAUDITED)

In order to continue as a going concern and to develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management’s plans to continue as a going concern include raising additional capital through borrowing and/or sales of equity and debt securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.

Recently Issued Standards

In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The purpose is to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information. This ASU is effective for the Company in the first quarter of 2018. Early adoption is not permitted except for limited provisions. The Company does not expect the adoption of this amendment to have a material effect on its financial condition and results of operations.

In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This new standard became effective for the Company on January 1, 2017. The adoption of this standard did not have a material impact on its financial position, results of operations or statements of cash flows upon adoption.

In August, 2016, the FASB issued Accounting Standards Update No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force) (“ASU 2016-15”). The amendments in ASU 2016-15 address eight specific cash flow issues and apply to all entities that are required to present a statement of cash flows under ASC Topic 230, Statement of Cash Flows. The amendments in ASU 2016-15 are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption during an interim period. The Company has not yet completed the analysis of how adopting this guidance will affect its consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for the Company on January 1, 2018; however, early adoption is permitted with prospective application to any business development transaction.

In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation: Scope of Modification Accounting, which provides clarification on when modification accounting should be used for changes to the terms or conditions of a share-based payment award. This ASU does not change the accounting for modifications but clarifies that modification accounting guidance should only be applied if there is a change to the value, vesting conditions or award classification and would not be required if the changes are considered non-substantive. The amendments of this ASU are effective for the Company in the first quarter of 2018, with early adoption permitted. The adoption of ASU 2017-09 is not expected to have an impact on the Company’s consolidated financial statements.

There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

10

Table of Contents

CURE PHARMACEUTICAL HOLDING CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

(UNAUDITED)

NOTE 3 - INVENTORY

Inventory consists of raw materials, packaging components, work-in-process and finished goods. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or market. The carrying value of inventory consisted of the following at June 30, 2017 and December 31, 2016:

	June 30, 2017			December 31, 2016
Raw materials	$	74,678		$	68,047
Packaging components		97,782			84,927
Work-in-process		23,461			17,406
Finished goods		-			-
		195,921			170,380
Reserve for obsolescence		(91,932	)		(89,095	)
Total inventory	$	103,989		$	81,285

NOTE 4 – PREPAID EXPENSES AND OTHER ASSETS

As of June 30, 2017 and December 31, 2016, prepaid expenses and other assets consisted of the following:

	June 30, 2017		December 31, 2016

Prepaid consulting services	$	1,011,155	$	150,168
Prepaid clinical study		642,500		-
Prepaid insurance		19,270		42,785
Other Receivables		10,178		10,948
Prepaid inventory		6,927		13,178
Prepaid expenses		5,900		6,800
Property and Equipment, net	$	1,695,930	$	223,879

NOTE 5 – PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS

As of June 30, 2017 and December 31, 2016, property and equipment and intangible assets consisted of the following:

	June 30, 2017			December 31, 2016

Manufacturing equipment	$	769,074		$	769,074
Computer and other equipment		147,192			116,747
Leasehold improvements		36,066			36,066
Less accumulated depreciation		(627,681	)		(551,239	)
Property and Equipment, net	$	324,651		$	370,648

11

Table of Contents

CURE PHARMACEUTICAL HOLDING CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

(UNAUDITED)

Depreciation expense for the three and six months ended June 30, 2017 was $37,437 and $76,442, respectively, which includes depreciation of $2,160 and $4,320 for capitalized leased assets for the three and six months ended June 30, 2017, respectively. Depreciation expense for the three and six months ended June 30, 2016 was $26,507 and $54,062, respectively, which includes depreciation of $2,160 and $4,320 for capitalized leased assets for the three and six months ended June 30, 2016, respectively. The total amount of property held under a under a capital lease was $43,201 as of June 30, 2017 and December 31, 2016. Accumulated depreciation for property held under capital leases were $32,857 and $28,537 as of June 30, 2017 and December 31, 2016 respectively.

	June 30, 2017			December 31, 2016

Intellectual Property	$	814,582		$	814,582
Patents		191,602			175,047
Less accumulated amortization		(116,839	)		(95,119	)
Intangible assets, net	$	889,345		$	894,510

The Company incurred $16,555 and $45,930 of legal patent costs that were capitalized during the six months ended June 30, 2017 and the year ended December 31, 2016, respectively. The Company did not write off any intangibles during the six months ended June 30, 2017 and wrote off $58,522 of intangibles during the year ended December 31, 2016. Amortization expense for the three and six months ended June 30, 2017 was $10,821 and $21,720, respectively. Amortization expense for the three and six months ended June 30, 2016 was $10,667 and $21,332, respectively.

The estimated aggregate amortization expense over each of the next five years is as follows:

2017	$	21,798
2018		43,518
2019		43,518
2020		43,518
2021		43,518
Thereafter		557,303
Total Amortization	$	753,172

12

Table of Contents

CURE PHARMACEUTICAL HOLDING CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

(UNAUDITED)

NOTE 6 – LOAN PAYABLE

Loan payable consist of the following at June 30, 2017 and December 31, 2016:

	2017		2016
Note to a company due September 29, 2017 including interest at 13.25% per annum; unsecured; interest due monthly	$	11,460	$	33,277
Current portion of loan payable		11,460		33,277
Loan payable, less current portion	$	-	$	-

NOTE 7 – NOTE PAYABLE

Notes payable consist of the following at June 30, 2017 and December 31, 2016:

	2017			2016

Note to a company due August 27, 2017, no interest shall accrue unless and until an event of default occurs, where interest at 10% per annum shall accrue beginning on the date of the applicable event of default, secured by the Company’s intellectual property	$	650,000		$	-
Note to an individual, non-interest bearing, unsecured and has no fixed terms of repayment		50,000			50,000

		700,000			50,000
Unamortized discount		(4,750	)		-
Current portion of loan payable		695,250			50,000
Loan payable, less current portion	$	-		$	-

During the three and six months ended June 30, 2017, the Company incurred $5,250 amortization of discount. During the three and six months ended June 30, 2016, the Company incurred $0 amortization of discount.

NOTE 8 – CONVERTIBLE PROMISSORY NOTES

Convertible promissory notes consist of the following at June 30, 2017 and December 31, 2016:

	2017			2016

Convertible promissory notes totaling $700,000 due between November 11, 2017 and December 30, 2017, interest payable at 8% per annum; unsecured; principal and accrued interest convertible into common stock at the lower of $7.00 per share or the price per share of the latest closing of a debt or equity offering by the Company greater than $3,000,000; accrued interest due between November 11, 2017 and December 30, 2017	$	700,000		$	-

		700,000			-
Unamortized discount		(599,063	)		-
Current portion of convertible promissory notes		100,937			-
Convertible promissory notes, less current portion	$	-		$	-

During the three and six months ended June 30, 2017, the Company incurred $77,683 amortization of discount. During the three and six months ended June 30, 2016, the Company incurred $0 amortization of discount. During the three and six months ended June 30, 2017, the Company incurred $3,306 interest expenses and accrued interest as of June 30, 2017. During the three and six months ended June 30, 2016, the Company incurred $0 interest expenses and accrued interest as of June 30, 2016.

13

Table of Contents

CURE PHARMACEUTICAL HOLDING CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

(UNAUDITED)

NOTE 9 – DERIVATIVE LIABILITY

The following table summarizes fair value measurements by level at June 30, 2017 for assets and liabilities measured at fair value on a recurring basis:

	Level I		Level II		Level III			Total
Cash	$	277,961	$	—	$	—		$	277,961

Derivative liability		—		—	$	(412,777	)	$	(412,777	)

No financial assets or liabilities were measured on a recurring basis as of December 31, 2016.

The Company has issued convertible promissory notes during 2017. The convertible notes require us to record the value of the conversion feature as a liability, at fair value, pursuant to ASC 815, including provisions in the notes that protect the holders from declines in the Company’s stock price, which is considered outside the control of the Company. The derivative liabilities are marked-to-market each reporting period and changes in fair value are recorded as a non-operating gain or loss in our statement of operations, until they are completely settled. The fair value of the conversion feature is determined each reporting period using the Black-Scholes option pricing model, and is affected by changes in inputs to that model including our stock price, expected stock price volatility, interest rates and expected term. The assumptions used in valuing the derivative liability during 2017 were as follows:

		June 30, 2017
Significant assumptions (weighted-average):
Risk-free interest rate at grant date		1.89%
Expected stock price volatility		79.92%
Expected dividend payout		-
Expected option life (in years)		1
Expected forfeiture rate		0%

The following is a reconciliation of the derivative liability for 2017:

	June 30, 2017
Value at December 31, 2016	$	-
Initial value at the debt issuance		370,232
Increase in value		42,545
Value at June 30, 2017	$	412,777

NOTE 10 – WARRANT AGREEMENTS

On January 3, 2017, the Company issued 1,300,000 warrants in connection with commissions earned in relation to the Company’s Private Label Exclusive Distribution and License agreement with Red Barn Pet Products, LLC.

From May 11, 2017 to June 30, 2017, the Company issued 140,000 warrants in connection with the issuance of $700,000 convertible promissory notes.

Warrants that vest at the end of a one-year period are amortized over the vesting period using the straight-line method.

The Company’s warrant activity was as follows:

	Warrants		Weighted Average Exercise Price		Weighted Average Contractual Remaining Life
Outstanding, December 31, 2016		4,392,107		1.97		6.17
Granted		1,440,000		2.49		0.75
Exercised		-		-		-
Forfeited/Expired		-		-		-
Outstanding, June 30, 2017		5,832,107		2.10		5.92
Exercisable at June 30, 2017		3,6630,665		2.19		2.95

14

Table of Contents

CURE PHARMACEUTICAL HOLDING CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

(UNAUDITED)

Range of

Exercise Price

Number of

Warrants

Weighted Average Remaining Contractual Life (years)

Weighted Average Exercise Price

Number of Warrants Exercisable

Weighted Average Exercise Price

$1.00 - $7.00

5,832,107

5.92

2.10

3,630,665

2.19

5,832,107

5.92

2.10

3,630,665

2.19

The weighted-average fair value of warrants granted to during the three months ended June 30, 2017 and year ended December 31, 2016, and the weighted-average significant assumptions used to determine those fair values, using a Black-Scholes-Merton (“Black-Scholes”) option pricing model are as follows:

	June 30, 2017			December 31, 2016
Significant assumptions (weighted-average):
Risk-free interest rate at grant date		1.89	%		1.83	%
Expected stock price volatility		79.92	%		84.42	%
Expected dividend payout		-			-
Expected option life (in years)		3			3
Expected forfeiture rate		0	%		0	%

NOTE 11 – STOCKHOLDERS’ EQUITY

Authorized Stock

The Company has authorized to issue is 75,000,000 common shares with a par value of $0.001 per share.

As of June 30, 2017 and December 31, 2016, there were 23,751,252 and 23,336,673, shares of the Company’s common stock issued and outstanding, respectively.

Common Share Issuances

On April 7, 2017, the Company issued 14,579 common stock shares at $6.86 per share for consulting services to be performed over a one year period. The total value of this issuance was $100,000 and as of June 30, 2017, $76,986 is included in prepaid expenses and other assets.

On April 24, 2017, the Company issued 100,000 common stock shares at $7.00 per share for consulting services to be performed over a six month period. The total value of this issuance was $700,000 and as of June 30, 2017, $443,716 is included in prepaid expenses and other assets.

On May 18, 2017, the Company issued 300,000 common stock shares at $2.10 per share for consulting services to be performed over a one year period. The total value of this issuance was $630,000 and as of June 30, 2017, $357,288 is included in prepaid expenses and other assets.

NOTE 12 - COMMITMENTS AND CONTINGENCIES

Litigation:

From time to time the Company may become a party to litigation in the normal course of business. Management believes that there are no current legal matters that would have a material effect on the Company’s financial position or results of operations.

15

Table of Contents

CURE PHARMACEUTICAL HOLDING CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

(UNAUDITED)

Operating leases

The Company maintains its corporate offices and manufacturing facility at 1620 Beacon Place, Oxnard, CA 93033, which contains approximately 25,000 square feet. The Company is currently on a month-to-month lease.

The Company also leases additional office and warehouse space at 1610 and 1612 Fiske Place, Oxnard, CA 93033, which contains approximately 6,547 square feet. The Company is currently on a month-to-month lease.

Total rent expense for the three and six month periods ended June 30, 2017 was $73,416 and $145,815, respectively. Total rent expense for the three and six month periods ended June 30, 2016 was $72,101 and $142,569, respectively.

NOTE 13 – LEGAL PROCEEDINGS

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. The only significant matter of which the Company is aware of is discussed below.

On May 22, 2017, Sandy Sierra Garate (“Applicant”), an employee of the Company, filed an application for benefits due to serious and willful misconduct of the employer pursuant to labor code section 4553 with the State of California Workers’ Compensation Appeals Board (WCAB Case No: ADJ 10686812) resulting in injury arising out of and in the course of the Applicant’s employment on August 5, 2016. The Applicant is requesting relief in this matter for a one half increase in all compensation recoverable in connection with the injury of August 5, 2016, for the allowance of costs and expenses in an amount to be determined and for such further relief as in deemed appropriate. The Company is currently unable to determine what the additional expenses will be incurred in order to defend this matter. As such, the Company cannot determine whether there is a reasonable possibility that a loss will be incurred nor can it estimate the range of any such potential loss. Accordingly, the Company has not accrued an amount for any potential loss associated with this action.

NOTE 14 – SUBSEQUENT EVENTS

On July 19, 2017, the Company entered into a Development Agreement (“Agreement”) with Aveneon Technology, Ltd (“Aveneon”) for the development and formulation of certain active ingredients utilizing our proprietary CureFilm™ technology. In consideration of the development activities specified hereunder, Aveneon paid the Company a non-refundable and non-creditable fee of $35,692 (the “Initial Fee”) within one (1) day of the Effective Date. Aveneon shall pay the Company the following non-refundable and non-creditable milestone payment of $35,692 (the “Milestone Payment”) within fifteen (15) days after initiation of Phase IV – Product Conformance.

On July 27, 2017, the Company received $300,000 by issuing a convertible promissory note (“Convertible Note”) to an individual that is due January 27, 2018 (“Maturity Date”). The Convertible Note shall accrue interest at 8% per annum and is unsecured. The conversion price of the Common Stock into which the Principal Amount, or the then outstanding interest due thereon, shall be the lower of $7.00 or the price per share of the latest closing of a debt or equity offering by the Company greater than $3,000,000. Pursuant to issuing this Convertible Note, the Company issued to the holder of this Convertible Note a warrant to purchase 60,000 shares of Common Stock at an exercise price at the lower of $7.00 per share or the price per share of the latest closing of a debt or equity offering by the Company greater than $3,000,000.

16

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Statements made in this Form 10-Q that are not historical or current facts are “forward-looking statements” made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 (the “Act”) and Section 21E of the Securities Exchange Act of 1934. These statements often can be identified by the use of terms such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “approximate” or “continue,” or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management’s best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

BUSINESS

CURE Pharmaceutical Holding Corp. (the “Company”) was incorporated in the State of Nevada on May 15, 2014. The Company was formerly named Makkanotti Group Corp. and was formed to engage in the business of manufacturing food paper bags in Nicosia, Cyprus.

On November 7, 2016, the board of directors and the majority stockholder of the then outstanding shares of the registrant’s common stock executed a written consent to change the registrant’s name to CURE Pharmaceutical Holdings Corp. from Makkanotti Group Corp. The Certificate of Amendment to Articles of Incorporation was filed with the State of Nevada on November 30, 2016.

CURE Pharmaceutical Corporation

Our wholly owned subsidiary and operating business, Cure Pharmaceutical, located in Oxnard, California was originally incorporated in July 2011 as a developer of advanced oral thin film (“OTF”) for the delivery of nutraceutical, Over-The-Counter (“OTC”) and prescription products for human and veterinary markets. We utilize drug delivery technologies to develop and commercialize new applications of proven therapeutics through our CureFilm™ technology, as well as through sublingual and transdermal applications. Our exclusive micro encapsulation of drug actives allows for a higher volume of an active and if required, multiple actives to be produced on a single OTF strip. We expect this technology will allow us to produce a broad spectrum of pharmaceutical, OTC and nutraceutical products.

Our Product

CureFilm™ Technology and Value Proposition

Typical forms of drug delivery that consumers have been familiar with over the years, include tablets, capsules, chewables, gummies, and more recent developments, such as melts and sublingual drops and sprays. We believe that we are one of the companies at the forefront of OTF drug delivery technology. Our OTF product is about the size of a postage stamp using a matrix that maximizes the amount of “active” drug that can be delivered via OTF.

Our CureFilm™ Technology consists of patented, patent pending and trade secrets in two areas: OTF – Core Technology, Sublingual Technology and Transdermal (skin) Technology.

Our proprietary multi-layer CureFilm™ allows dosages of many pharmaceutical, OTC and nutraceutical products to be put onto a small strip applied to the cheek (buccal), or under the tongue (sublingual). We believe that what sets us apart from the competition is our proprietary patented CureFilm™ Technology, multi-layer systems and formulation technologies that:

	·	Consists of two components - a liquid-based film layer that contains and stabilizes the active ingredients, and a powder matrix layer.
	·	Provides improved stability as well as delivery of active ingredients.
	·	Contains functional qualities to include extra flavoring ingredients, pliability enhancers, and mucosal permeation enhancers.

In a two-layer strip, the layers are designed to work together, in combination with the powder composition. The powder composition can be varied, as can the muco-adhesion properties of the strips, to alter the dissolution and absorption rates of the medicament. A complete multilayer system allows for increased stability, higher loading of active ingredients, and increased taste and palatability.

17

Table of Contents

Another recent advancement in our CureFilm™ Technology utilizes micro-encapsulation of selected active ingredients. In the micro-encapsulation process, microscopic particles or droplets envelop the active ingredients to protect and shield them. The technique used in the micro-encapsulation process depends on various factors including the physical and chemical properties of the active ingredients. This micro-encapsulation technology has allowed the delivery of higher dosing with better flavor masking.

We have various types of CureFilm™ dietary supplement products that are being commercialized and developed. These include:

Commercialized:

	·	MacuStrip Vitamin complex (eye health product)
	·	ID Life Sleep melatonin
	·	Electrolyte (Adult and Pediatric)
	·	E6 Berry Caffeine
	·	Hang-Over Relief

In Development:

	·	Aspirin
	·	Loratadine
	·	Tadalifil
	·	Sildenafil
	·	Loperamide
	·	Vitamin B12
	·	Vitamin D3
	·	Folic Acid

Clinical Development

We partner with pharmaceutical companies looking for new methods to deliver drug actives. Under Section (505)(b)(2) of the Food, Drug, and Cosmetic Act, (“(505)(b)(2)”) the FDA may grant market exclusivity for a term of up to three years of exclusivity following approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage, dosage form, route of administration or combination. The 505(b)(2) pathway is also the regulatory approach to be followed if an applicant intends to file an application for a product containing a drug that is already approved by the FDA for a certain indication and for which the applicant is seeking approval for a new indication or for a new use, the approval of which is required to be supported by new clinical trials, other than bioavailability studies. We have implemented a strategy under which we actively look for such so-called “repurposing opportunities” and determine whether our proprietary CureFilm™ Technology adds value to the product.

We currently have five such drug repurposing projects in our development pipeline, although there can be no assurance that such projects will be fully developed. The companies we partner with are typically responsible for managing the regulatory approval process of the product with the FDA and/or other regulatory bodies, as well as for the marketing and distribution of the products. On a case-by-case basis, we may be responsible for providing all or part of the documentation required for the regulatory submission.

In addition to pursuing partnering arrangements that provide for the full funding of a drug development project, we may undertake development of selected product opportunities until the marketing and distribution stage. We would first assess the potential and associated costs for successful development of a product, and then determine at which stage it would be most prudent to seek a partner, balancing costs against the potential for higher returns later in the development process. We currently have five of such potential drug candidates in our product pipeline, all of which are in the formulation development and pre-clinical phase of development. However, there can be no assurance that we will be able to fully develop, market and distribute OTF products for these drug candidates.

18

Table of Contents

Memorandums of Understanding

Competition

We face competition from other companies, academic institutions, governmental agencies and other public and private research organizations for collaborative arrangements with pharmaceutical and biotechnology companies, in recruiting and retaining highly qualified scientific and management personnel and for licenses to additional technologies. Many of our competitors, including Monosol, BioDelivery Sciences International, IntelGenx and LTS Lohmann, will have substantially greater financial, technical and human resources than we have. Our success will be based in part on our ability to build, obtain regulatory approval for and market acceptance of, and actively manage a portfolio of drugs that addresses unmet medical needs and creates value in patient therapy.

The OTF manufacturing industry is relatively new, having only emerged over the last ten years. Although currently there are just a handful of current players within this industry, we expect that we will be subject to competition from numerous other companies that currently operate or are planning to enter the markets in which we compete. To date, among manufacturers of OTF, some medications that either are or have been available by OTF manufacturers in the marketplace include:

	·	Zuplenz (the first oral soluble film approved by the FDA as a prescription medication)
	·	Benadryl (diphenhydramine product and anti-histamine used for allergies and mild sedative)
	·	Gas-X (simethicone product for bloating, gas, and gastrointestinal complaint)
	·	Melatonin PM (hormonal product sold as a “dietary supplement” marketed for insomnia)
	·	Orajel Kids (benzocaine product for dental pain)
	·	Suboxone (buprenorphine and naloxone fixed dosage combination product for opioid addiction)
	·	Subutex (buprenorphine product for opioid addiction)
	·	Sudafed (phenylephrine or pseudoephedrine product for nasal congestion)
	·	TheraFlu (combination product of pain reliever, anti-pyretic and decongestant)
	·	Triaminic (children’s anti-tussive product)

The barriers to enter this market are the “know how’s” of developing and formulating consumer desired products which taste great. Also, the high cost of entry by companies who have no expertise in the market makes entry by competitors risky since the technology to develop product is expensive and proprietary. The key factors affecting the development and commercialization of our drug delivery products are likely to include, among other factors:

	·	The safety and efficacy of our products;
	·	The relative speed with which we can develop products;
	·	Generic competition for any product that we develop;
	·	Our ability to defend our existing intellectual property and to broaden our intellectual property and technology base;
	·	Our ability to differentiate our products;
	·	Our ability to develop products that can be manufactured on a cost effective basis;
	·	Our ability to manufacture our products in compliance with cGMP and any other regulatory requirements; and
	·	Our ability to obtain financing.

In order to establish ourselves as a viable industry partner, we plan to continue to invest in our research and development activities and in our manufacturing technology expertise, in order to further strengthen our technology base and to develop the ability to manufacture our CureFilm™ products ourselves, at competitive costs. Our failure to compete effectively could have a material adverse effect on our business.

Office

Our office is located at 1620 Beacon Place, Oxnard, California 93033. Our phone number is (805) 824-0410.

19

Table of Contents

RESULTS OF OPERATIONS

Revenues for the Three and Six Months Ended June 30, 2017 and 2016.

Revenues for the three and six months ended June 30, 2017 has increased by $21,734 and $25,070, respectively, as compared to the three and six months ended June 30, 2016. The increase in both periods was principally due to the increase in sales to one customer for our Sleep OTF product. In addition, the increase in the six months ended June 30, 2017 compared to the same period in 2016 is due to the Company completing a couple of R&D phases with two customers. The Company did not generate this type of revenue in the six months ended June 30, 2016.

Cost of Goods Sold

Cost of goods sold was $39,958 and $75,148 in the three and six months ended June 30, 2017, respectively, compared to $10,759 and $37,744 in the three and six months ended June 30, 2016, respectively. Cost of goods sold increased in both periods due to the Company utilizing a new third party converter for one of our customers as well as incurring higher direct labor costs to package our Sleep OTF product. In addition, the Company incurred higher sales in both the three and six months ended June 30, 2017 compared to the same periods in 2016 resulting in higher cost of goods sold in the three and six months ended June 30, 2017 compared to the same periods in 2016.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three and six months ended June 30, 2017 amounted to $2,194,950 and $4,597,497, respectively, and for three and six months ended June 30, 2016 amounted to $304,669 and $596,605, respectively. For the three and six months ended June 30, 2017 and 2016, selling, general and administrative expenses were mainly comprised of amortization, commission, insurance, payroll, consulting, marketing, legal, accounting, public market and rent expenses. The increase in the three and six months ended June 30, 2017 compared to the three and six months ended June 30, 2016 was due to the increase in payroll, insurances and public market expenses as well as noncash transactions relating to common stock to be issued for consulting services and recording the fair value of the warrants issued for services totaling $1,917,637 and $3,269,630 for the three and six months ended June 30, 2017, respectively. In addition, the Company has started to focus on rebranding the Company as well as strategizing which pharmaceutical markets, industries and particular indications the company will focus our efforts in.

Research and Development Expenses

For the three and six months ended June 30, 2017, research and development expenses increased to $205,648 and $425,268, respectively, compared to the three and six months ended June 30, 2016 of $171,447 and $298,799, respectively. As the Company was able to raise funds during 2016 by issuing convertible promissory notes, we were able to continue to focus on spending on improving our intellectual property. At the same time the Company focused on developing potential partnerships with pharmaceutical and bioscience companies and new OTC and prescription products.

LIQUIDITY AND CAPITAL RESOURCES

For the six months ended June 30, 2017

As of June 30, 2017, our total assets were $3,439,197 comprised of cash of $277,961, accounts receivable of $13,443, inventory of $103,989, prepaid expenses and other assets of $1,695,930, net property and equipment of $324,651, net intangibles of $889,345, and other assets of $133,878. Our total liabilities were $2,429,435 comprised of accounts payable of $416,736, accrued expenses of $36,441, current portion of loan and note payables of $706,710, current portion of capital lease payable of $3,234, current portion of convertible promissory notes of $100,937, derivative liability of $412,777, deferred revenue of $192,600 and license fees of $560,000.

Cash flows used in operating activities

For the months ended June 30, 2017, operating activities consumed $2,075,795 of cash. This was primarily the result of a net loss of $5,161,425, offset by depreciation and amortization of $98,162, amortization of prepaid stock-based compensation of $552,010, amortization of loan discounts of $82,933, warrants issued for services of $2,717,620 as well as the changes in inventory of $22,704, prepaid expenses of $594,061, accounts payable of $151,350 and deferred revenue of $18,982.

Cash flows used in investing activities

Investment activities used an additional $64,350 of cash during the six months ended June 30, 2017, primarily as a result of payments for patents and costs associated in the development and improvement of our intellectual property of $16,555, payment to joint venture investment of $5,000 and acquisition of property and equipment of $42,795.

Cash flows provided by financing activities

Financing activities provided $1,311,964 of cash for the six months ended June 30, 2017, primarily as the result of proceeds from loans of $1,340,000 and repayments of loan and capital lease payables of $28,036.

20

Table of Contents

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in conformity with generally accepted accounting principles of the United States (“U.S. GAAP”) requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities in the financial statements and accompanying notes. The SEC has defined a company’s critical accounting policies as the ones that are most important to the portrayal of the company’s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the critical accounting policies and judgments addressed below. We also have other key accounting policies, which involve the use of estimates, judgments, and assumptions that are significant to understanding our results. For additional information, see Note 2 – “Summary of Significant Accounting Policies”. Although we believe that our estimates, assumptions, and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments, or condition

Impairment of Long-Lived Assets

Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the fair value of the asset (or asset group), typically a discounted cash flow analysis, and an impairment charge is recorded for the excess of carrying value over fair value. There was no impairment on our long-lived assets during the three months ended June 30, 2017. For the year ended December 31, 2016, the Company wrote off $58,522 of patents.

Going Concern

The Company has an accumulated deficit balance as of June 30, 2017. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. The Company is continually analyzing its current costs and is attempting to make additional cost reductions where possible. We expect that we will continue to generate losses from operations throughout the remainder of 2017.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.

OFF-BALANCE SHEET ARRANGEMENTS

As of the date of this Quarterly Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not Applicable.

21

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(t) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:

	1.	Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

	2.	Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with the authorization of our management and directors; and

	3.	Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of our internal control over financial reporting as of June 30, 2017. Based on this assessment, management concluded that the Company did not maintain effective internal controls over financial reporting as a result of the identified material weakness in our internal control over financial reporting described below. In making this assessment, management used the framework set forth in the report entitled Internal Control--Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO. The COSO framework summarizes each of the components of a company’s internal control system, including (i) the control environment, (ii) risk assessment, (iii) control activities, (iv) information and communication and (v) monitoring.

Identified Material Weakness

A material weakness in our internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement or the financial statements will not be prevented or detected. Management identified the segregation of duties as a material weakness during its assessment of internal controls over financial reporting as of June 30, 2017. As of June 30, 2017, we had one full-time employee with the requisite expertise in the key functional areas of finance and accounting. As a result, there is a lack of proper segregation of duties necessary to ensure that all transactions are accounted for accurately and in a timely manner. As our resources allow, we will add financial personnel to our management team.

Changes In Internal Control Over Financial Reporting

There were no changes in our internal controls over financial reporting during the fiscal quarter ended June 30, 2017 that materially affected, or is reasonably likely to have a material affect, on our internal control over financial reporting.

22

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The information set forth under Note 13 of Notes to Unaudited Condensed Consolidated Financial Statements, included in Part I, Item 1 of this report, is incorporated herein by reference.

ITEM 1A. RISK FACTORS

Not Applicable.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On April 7, 2017, the Company issued 14,579 common stock shares at $6.86 per share for consulting services to be performed over a one year period.

On April 24, 2017, the Company issued 100,000 common stock shares at $7.00 per share for consulting services to be performed over a six month period.

On May 18, 2017, the Company issued 300,000 common stock shares at $2.10 per share for consulting services to be performed over a one year period.

The shares of common stock described above were issued without registration under the Securities Act of 1933 (the “Securities Act”) in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act promulgated thereunder and in reliance on similar exemptions under applicable state laws.

From May 11, 2017 to June 30, 2017, the Company issued 140,000 warrants in connection with the issuance of $700,000 convertible promissory notes. The warrants have an exercise price of the lower of $7.00 per share or the price per share in the Company’s latest debt or equity financing greater than $3,000,000 and a term of 3 years.

On April 27, 2017, the Company received $640,000 by issuing a senior secured promissory note in the face amount of $650,000 due August 27, 2017. No interest shall accrue on this note unless it is not repaid by the maturity date at which the note shall accrue interest at 10% per annum. The note is secured by the Company’s intellectual property.

From May 11, 2017 to June 30, 2017, the Company issued up to $700,000 convertible promissory notes due between November 11, 2017 and December 30, 2017. The notes bear interest at 8% per year and are convertible into common stock at the lower of $7.00 per share or the price per share in the Company’s latest debt or equity financing greater than $3,000,000.

The warrants and notes described above were issued and sold without registration under the Securities Act in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws.

ITEM 3. DEFAULTS UPON SENIOR SECURITES

None.

ITEM 4. MINE SAFETY DISCLOSURE

None.

ITEM 5. OTHER INFORMATION

None.

23

Table of Contents

ITEM 6. EXHIBITS

31.1		Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

24

Table of Contents

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CURE PHARMACEUTICAL HOLDING CORP.

Dated: August 14, 2017	By:	/s/ Robert Davidson
		Robert Davidson
		Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

/s/ Robert Davidson
Robert Davidson
Chief Executive Officer
August 14, 2017

/s/ Mark Udell
Mark Udell
Chief Financial Officer
August 14, 2017

EX-31.1 2 curr_ex311.htm CERTIFICATION curr_ex311.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13A-14 OF THE EXCHANGE ACT OF 1934

CERTIFICATION

I, Robert Davidson, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of CURE Pharmaceutical Holding Corp.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures, to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal year (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2017

By:

/s/ Robert Davidson

Robert Davidson

Chief Executive Officer and

Principal Executive Officer

EX-31.2 3 curr_ex312.htm CERTIFICATION curr_ex312.htm

EXHIBIT 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13A-14 OF THE EXCHANGE ACT OF 1934

CERTIFICATION

I, Mark Udell, certify that:

1.

I have reviewed this quarterly report on Form 10-Q of CURE Pharmaceutical Holding Corp.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2017

By:

/s/ Mark Udell

Mark Udell

Chief Financial Officer

EX-32.1 4 curr_ex321.htm CERTIFICATION curr_ex321.htm

EXHIBIT 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CURE Pharmaceutical Holding Corp., (the “Company”) on Form 10-Q for the three months ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert Davidson, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2017

By:

/s/ Robert Davidson

Robert Davidson

Chief Executive Officer and

Principal Executive Officer

EX-32.2 5 curr_ex322.htm CERTIFICATION wordproof.doc

EXHIBIT 32.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CURE Pharmaceutical Holding Corp., (the “Company”) on Form 10-Q for the three months ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark Udell, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2017	By:	/s/ Mark Udell
		Mark Udell
		Chief Financial Officer

EX-101.INS 6 curr-20170630.xml XBRL INSTANCE DOCUMENT 0001643301 2017-01-01 2017-06-30 0001643301 2017-08-10 0001643301 2016-12-31 0001643301 2016-01-01 2016-06-30 0001643301 2016-06-30 0001643301 2017-06-30 0001643301 us-gaap:LeaseholdImprovementsMember 2017-01-01 2017-06-30 0001643301 curr:ManufacturingEquipmentMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0001643301 us-gaap:ComputerEquipmentMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0001643301 us-gaap:ComputerEquipmentMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0001643301 2016-01-08 0001643301 us-gaap:ComputerEquipmentMember 2016-12-31 0001643301 us-gaap:IntellectualPropertyMember 2016-12-31 0001643301 us-gaap:PatentsMember 2016-12-31 0001643301 curr:ConvertiblePromissoryNotesMember 2016-12-31 0001643301 us-gaap:WarrantMember 2016-01-01 2016-12-31 0001643301 us-gaap:WarrantMember 2016-12-31 0001643301 us-gaap:LoansPayableMember 2016-12-31 0001643301 us-gaap:LoansPayableMember 2017-06-30 0001643301 2015-12-31 0001643301 curr:ManufacturingEquipmentMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0001643301 curr:LicenseAgreementMember 2017-01-01 2017-01-03 0001643301 2017-04-01 2017-06-30 0001643301 2016-04-01 2016-06-30 0001643301 us-gaap:ResearchAndDevelopmentExpenseMember 2017-05-01 0001643301 2016-01-01 2016-12-31 0001643301 us-gaap:EquipmentMember 2017-06-30 0001643301 us-gaap:LeaseholdImprovementsMember 2017-06-30 0001643301 us-gaap:EquipmentMember 2016-12-31 0001643301 us-gaap:ComputerEquipmentMember 2017-06-30 0001643301 us-gaap:LeaseholdImprovementsMember 2016-12-31 0001643301 us-gaap:IntellectualPropertyMember 2017-06-30 0001643301 us-gaap:PatentsMember 2017-06-30 0001643301 us-gaap:AssetsLeasedToOthersMember 2017-04-01 2017-06-30 0001643301 us-gaap:AssetsLeasedToOthersMember 2017-01-01 2017-06-30 0001643301 us-gaap:AssetsLeasedToOthersMember 2016-04-01 2016-06-30 0001643301 us-gaap:AssetsLeasedToOthersMember 2016-01-01 2016-06-30 0001643301 us-gaap:AssetsHeldUnderCapitalLeasesMember 2017-06-30 0001643301 us-gaap:AssetsHeldUnderCapitalLeasesMember 2016-12-31 0001643301 us-gaap:LoansPayableMember 2017-01-01 2017-06-30 0001643301 curr:ConvertiblePromissoryNotesMember 2017-06-30 0001643301 curr:CompanyMember 2017-06-30 0001643301 curr:CompanyMember 2016-12-31 0001643301 us-gaap:IndividualMember 2017-06-30 0001643301 us-gaap:IndividualMember 2016-12-31 0001643301 us-gaap:FairValueInputsLevel1Member 2017-06-30 0001643301 us-gaap:FairValueInputsLevel2Member 2017-06-30 0001643301 us-gaap:FairValueInputsLevel3Member 2017-06-30 0001643301 curr:ExercisePriceRangeMember 2017-01-01 2017-06-30 0001643301 curr:ExercisePriceRangeMember 2017-06-30 0001643301 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001643301 curr:LicenseAgreementMember 2017-05-11 2017-06-30 0001643301 curr:LicenseAgreementMember 2017-06-30 0001643301 us-gaap:CommonStockMember curr:PrepaidExpensesAndOtherAssetsMember 2017-06-30 0001643301 us-gaap:CommonStockMember curr:PrepaidExpensesAndOtherAssetsOneMember 2017-06-30 0001643301 us-gaap:CommonStockMember curr:PrepaidExpensesAndOtherAssetsTwoMember 2017-06-30 0001643301 us-gaap:CommonStockMember 2017-05-18 0001643301 us-gaap:CommonStockMember 2017-04-24 0001643301 us-gaap:CommonStockMember 2017-04-07 0001643301 us-gaap:SubsequentEventMember us-gaap:IndividualMember 2017-07-27 0001643301 us-gaap:SubsequentEventMember us-gaap:IndividualMember 2017-07-01 2017-07-27 0001643301 us-gaap:SubsequentEventMember curr:MilestonePaymentMember 2017-07-19 0001643301 us-gaap:SubsequentEventMember 2017-07-19 0001643301 us-gaap:WarrantMember 2017-06-30 0001643301 curr:OfficesAndManufacturingFacilityMember 2017-06-30 0001643301 curr:OfficeAndWarehouseSpaceMember 2017-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft 0001643301 10-Q 2017-06-30 false --12-31 No No Yes Smaller Reporting Company 2017 1106142 2025787 277961 13352 277961 0.001 0.001 2.10 7.00 6.86 75000000 75000000 <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 61%; text-align: justify">Manufacturing equipment</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 37%; text-align: center">5-7 Years</td> <td style="width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; text-align: justify">Computer and other equipment</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">3-7 Years</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Leasehold Improvements</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">Lesser of useful life or the term of the lease</td> <td> </td></tr> </table> Q2 CURE PHARMACEUTICAL HOLDING CORP. 23336673 23751252 300000 100000 14579 State of Nevada 2014-05-15 Lesser of useful life or the term of the lease 250000 250000 0.50 95226 68893 1.00 221888 <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt">June 30, 2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">December 31, 2016</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Raw materials</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 11%; text-align: right">74,678</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">68,047</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Packaging components</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">97,782</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">84,927</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Work-in-process</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">23,461</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">17,406</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Finished goods</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">195,921</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">170,380</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Reserve for obsolescence</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(91,932</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(89,095</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Total inventory</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">103,989</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">81,285</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> Loan payable consist of the following at June 30, 2017 and December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2016</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Note to a company due September 29, 2017 including interest at 13.25% per annum; unsecured; interest due monthly</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; width: 9%; text-align: right">11,460</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; width: 9%; text-align: right">33,277</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Current portion of loan payable</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">11,460</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">33,277</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Loan payable, less current portion</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> Notes payable consist of the following at June 30, 2017 and December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2016</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Note to a company due August 27, 2017, no interest shall accrue unless and until an event of default occurs, where interest at 10% per annum shall accrue beginning on the date of the applicable event of default, secured by the Companys intellectual property</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">650,000</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Note to an individual, non-interest bearing, unsecured and has no fixed terms of repayment</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">50,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">50,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">700,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">50,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Unamortized discount</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(4,750</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Current portion of loan payable</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">695,250</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">50,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Loan payable, less current portion</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> The Companys warrant activity was as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Warrants</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Weighted Average Exercise Price</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Weighted Average Contractual Remaining Life</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Outstanding, December 31, 2016</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">4,392,107</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">1.97</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">6.17</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Granted</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">1,440,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">2.49</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">0.75</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Exercised</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Forfeited/Expired</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Outstanding, June 30, 2017</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">5,832,107</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">2.10</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">5.92</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Exercisable at June 30, 2017</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">3,6630,665</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">2.19</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">2.95</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">  Range of Exercise Price</td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Number of Warrants</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Weighted Average Remaining Contractual Life (years)</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Weighted Average Exercise Price</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Number of Warrants Exercisable</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Weighted Average Exercise Price</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 20%; border-bottom: black 1pt solid; text-align: center">$1.00 - $7.00</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; width: 13%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">5,832,107</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; width: 13%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">5.92</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify">$</td> <td style="vertical-align: bottom; width: 13%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">2.10</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; width: 13%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">3,630,665</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify">$</td> <td style="vertical-align: bottom; width: 13%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">2.19</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">5,832,107</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">5.92</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">2.10</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">3,630,665</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">2.19</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> The weighted-average fair value of warrants granted to during the three months ended June 30, 2017 and year ended December 31, 2016, and the weighted-average significant assumptions used to determine those fair values, using a Black-Scholes-Merton (Black-Scholes) option pricing model are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt">June 30, 2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">December 31, 2016</td> <td style="text-align: justify"> </td></tr> <tr> <td style="vertical-align: top; text-align: justify">Significant assumptions (weighted-average):</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Risk-free interest rate at grant date</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 11%; text-align: right">1.89</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">%</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 11%; text-align: right">1.83</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">%</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Expected stock price volatility</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">79.92</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">84.42</td> <td style="vertical-align: bottom; text-align: justify">%</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Expected dividend payout</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Expected option life (in years)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">3</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">3</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Expected forfeiture rate</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom; text-align: justify">%</td></tr> </table> P7Y P3Y P7Y P5Y 23751252 2835092 3439197 151579 133878 894510 889345 1418355 2091323 223879 1695930 7049 13443 1118039 2429435 560000 560000 558039 1869435 173618 192600 -412777 -412777 9453 3234 50000 695250 33277 11460 33277 11460 26305 36441 265386 416736 100937 23337 23752 12412430 16866149 -10718714 -15880139 1717053 1009762 2835092 3439197 23336673 23751252 23593105 6629260 23436696 6629260 -0.22 -0.16 -0.11 -0.09 -5161425 -1073112 -2541083 -597022 -5161425 -1073112 -2541083 -597022 -134342 -185724 -139772 -127478 89205 99321 87054 47603 7388 100634 6394 88491 -12351 -3323 -12351 17142 17142 8571 8571 5 412 1 45 -5027083 -887388 -2401311 -469544 5022765 895404 2400598 476116 4597497 596605 2194950 304669 425268 298799 205648 171447 -4318 8016 -713 6572 75148 37744 39598 10579 70830 45760 38885 17151 6812 3098 6812 3000 4448 59570 42662 32073 14151 -828181 2012435 1311964 4077201 6219 5509 21817 289253 1340000 4371963 -64350 -92647 42795 48830 5000 16555 25527 18290 -2075795 -1972119 18982 -28539 10136 46823 151350 -265682 -17213 -8858 594061 703838 22704 -12975 6394 -1679 50000 2717620 552010 -12351 -3323 -5488 98161 75394 2967 28892 1430000 82933 10000 676746 Cure Pharmaceutical Holding Corp (the Company), formerly known as Makkanotti Group Corp, was incorporated in the State of Nevada on May 15, 2014. The Company was formed to engage in the business of manufacturing food paper bags in Nicosia, Cyprus. On November 7, 2016, the Company changed its name to Cure Pharmaceutical Holding Corp.   On November 7, 2016, the Company, in a reverse take-over transaction, acquired Cure Pharmaceutical Corporation (Cure Pharmaceutical), a specialty pharmaceutical and bioscience company based in California that specializes in drug delivery technologies, by executing a Share Exchange Agreement and Conversion Agreement (Exchange Agreement) by and among the Company and a holder of a majority of the issued and outstanding capital stock of the registrant prior to the closing (the Majority Stockholder), on the one hand, and Cure Pharmaceutical, a California corporation, all of the shareholders of Cure Pharmaceuticals issued and outstanding share capital (the Cure Pharm Shareholders) and the holders of certain convertible promissory notes of Cure Pharmaceutical (Cure Pharm Noteholders), on the other hand. Hereinafter, this share exchange transaction is described as the Share Exchange. As a result of the Share Exchange, Cure Pharmaceutical became a wholly owned subsidiary of the Company, and the Cure Pharm Shareholders and Cure Pharm Noteholders became the controlling shareholders of the Company.   For accounting purposes, Cure Pharmaceutical shall be the surviving entity. The transaction is accounted for using the reverse acquisition method of accounting. As a result of the recapitalization and change in control, Cure Pharmaceutical is the acquiring entity in accordance with ASC 805, Business Combinations.   Cure Pharmaceutical Corporation is a specialty pharmaceutical and bioscience company with a focus in drug delivery technologies. Cure leverages novel drug delivery technologies to develop and commercialize new applications of proven therapeutics through Oral Thin Film (OTF) via our proprietary patented CureFilm Technology as well as through transdermal applications. Our micro encapsulation of drug actives in our CureFilm Technology allows for a higher volume of an active and if required, multiple actives to be produced on a single oral thin film strip.   The Company is focused on partnering with pharmaceutical and biotech companies seeking to deliver drug actives utilizing and benefitting from our proprietary OTF and transdermal applications and when preferable to take our own products from clinical process to commercialization. We are focused on both the human and veterinary prescription, OTC and nutraceutical markets. Cure represents the complete solution for OTF drug delivery therapeutics from inception to finished product utilizing our CGMP/FDA registered manufacturing facility and processes.   In July 2017 the Company, Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company dedicated to the development of cannabinoid-based drugs headquartered in Israel, and Assuta Medical Centers, Ltd., a medical services center located in Israel, entered into a nonbinding memorandum of understanding to collaborate to advance, research, develop and commercialize potential therapeutic products in the fields of personalized medicine and cannabinoids. The Company has not entered into any binding agreements or advanced any funds in connection with the foregoing.   The Company is still finalizing a research contract with Technion Research & Development Foundation Ltd. (TRDF) related to research regarding the effectiveness of certain cannabinoid strain extracts for specific genetic sub-types of cancer. On May 1, 2017, the Company paid $642,500 to initiate the research project with TRDF. Principles of Consolidation and Basis of Presentation   The condensed consolidated financial statements include the accounts of Cure Pharmaceutical Holding Corp (CPHC) and its wholly-owned subsidiary, Cure Pharmaceutical Corporation (Cure), collectively referred to as (Cure, we, us, our or the Company All significant inter-company balances and transactions have been eliminated in consolidation. The Companys film strip product represents the principal operations of the Company.   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (SEC). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Companys management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2017, and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2017 and 2016, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in Form 10-K for the fiscal period ended December 31, 2016 filed with the Securities and Exchange Commission (the SEC) on April 17, 2017.    Use of Estimates   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. These estimates and assumptions also affect the reported amounts of revenues, costs and expenses during the reporting period. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.   Cash and Cash Equivalents   The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents. As of June 30, 2017 and December 31, 2016, the Company had no cash equivalents. At June 30, 2017 and December 31, 2016, the Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions.   Investment in Associates   An associate is an entity over which the Company has significant influence through a joint venture. Significant influence is the power to participate in the financial and operating policy decisions of the investee but not control or joint control over those policies.   The results of assets and liabilities of associates are incorporated in the condensed consolidated financial statements using the equity method of accounting. Under the equity method, investments in associates are carried in the consolidated balance sheet at cost as adjusted for post-acquisition changes in the Companys share of the net assets of the associate, less any impairment in the value of the investment. Losses of an associate in excess of the Companys interest in that associate are not recognized. Additional losses are provided for, and a liability is recognized, only to the extent that the Company has incurred legal or constructive obligations or made payments on behalf of the associate.   Any excess of the cost of acquisition over the Companys share of the net fair value of the identifiable assets, liabilities and contingent liabilities of the associate recognized at the date of acquisition is recognized as goodwill. The goodwill is included within the carrying amount of the investment.   On January 8, 2016, the Company received 50% ownership in Cure Innovations, Inc (CI). CI was created in 2015 by IncuBrands Studio, Inc (IncuBrands). The Company and IncuBrands each own 50% of the common stock of CI. The Company and IncuBrands entered into a Joint Venture agreement in 2013 to distribute several OTF products utilizing IncuBrands marketing and contacts in various industries as well as utilize the Companys technology and capabilities of manufacturing OTFs.   On December 6, 2016, the Company entered into a Joint Venture Agreement (Joint Venture) with Pace Wellness, Inc. (Pace) to jointly develop three Active Pharmaceutical Ingredients (API) within the nonprescription and/or Over-the-Counter (OTC) medicines specifically utilizing the Companys patented and proprietary CureFilm Technology. The three APIs to be jointly developed are Diphenhydramine HCL, Omeprazole and a third API to be determined at a later date (Products). Pace shall be the exclusive global distributor of the Products under the Solves Strips® branding or other private or branded labels. All benefits, advantages, and liabilities derived from, or incurred in respect of the Joint Venture shall be borne by the parties in proportion of their respective participating interests of 50/50 equal interest.   Property and Equipment   The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred. Depreciation has been provided using the straight-line method on the following estimated useful lives:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 61%; text-align: justify">Manufacturing equipment</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 37%; text-align: center">5-7 Years</td> <td style="width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; text-align: justify">Computer and other equipment</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">3-7 Years</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Leasehold Improvements</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">Lesser of useful life or the term of the lease</td> <td> </td></tr> </table>    Accounts Receivable   Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and managements evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts.   Impairment of Long-Lived Assets   Long-lived assets include equipment and intangible assets other than those with indefinite lives. We assess the carrying value of our long-lived asset groups when indicators of impairment exist and recognize an impairment loss when the carrying amount of a long-lived asset is not recoverable when compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset.   Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the fair value of the asset (or asset group), typically a discounted cash flow analysis, and an impairment charge is recorded for the excess of carrying value over fair value. There were no impairments on our long-lived assets during the three and six month periods ended June 30, 2017 and 2016.   Revenue Recognition   The Company recognizes revenue in accordance with the FASB ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Company believes that these criteria are satisfied upon shipment from our facility. Freight billed to customers is presented as revenues, and the related freight costs are presented as cost of goods sold. Deferred revenue is recognized when earned and all significant obligations have been satisfied.   Advertising Expense   The Company expenses marketing, promotions and advertising costs as incurred. Such costs are included in general and administrative expense in the accompanying statements of operations. The Company recorded advertising costs of $68,893 and $95,226, for the three and six month periods ended June 30, 2017, respectively, and none for the three and six month periods ended June 30, 2016.   Research and Development   Costs incurred in connection with the development of new products and processes are charged to research and development expenses as incurred.   Income Taxes   The Company utilizes FASB ASC 740, Income Taxes, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is more likely-than-not that a deferred tax asset will not be realized.    The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of the Companys realization of the net operating loss carry forward prior to its expiration.   Stock-Based Compensation   Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.   Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the measurement date. The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date.   Fair Value Measurements   The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.   The estimated fair value of certain financial instruments, including cash and cash equivalents are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.   ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:   Level 1 quoted prices in active markets for identical assets or liabilities Level 2 quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 inputs that are unobservable (for example cash flow modeling inputs based on assumptions)   The Company has assets or liabilities valued at fair value on a recurring basis for the six months ended June 30, 2017. The Company did not have assets or liabilities valued at fair value on a recurring basis for the year ended December 31, 2016.   Basic and diluted loss per share   Basic loss per share is computed by dividing the net loss to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the net loss for the period by the weighted average number of common and dilutive common equivalent shares outstanding during the period. Common equivalent shares, which consist of stock options, warrants, and convertible notes payable, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.   Going Concern   The Companys financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit at June 30, 2017 of $15,880,139. The Company had a working capital of $221,888 as of June 30, 2017. These factors raise substantial doubt about the Companys ability to continue as a going concern for one year from the issuance of the financial statements. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. The Company is continually analyzing its current costs and is attempting to make additional cost reductions where possible. We expect that we will continue to generate losses from operations throughout 2017.    In order to continue as a going concern and to develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Managements plans to continue as a going concern include raising additional capital through borrowing and/or sales of equity and debt securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.   The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.   Recently Issued Standards   In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The purpose is to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information. This ASU is effective for the Company in the first quarter of 2018. Early adoption is not permitted except for limited provisions. The Company does not expect the adoption of this amendment to have a material effect on its financial condition and results of operations.   In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This new standard became effective for the Company on January 1, 2017. The adoption of this standard did not have a material impact on its financial position, results of operations or statements of cash flows upon adoption.   In August, 2016, the FASB issued Accounting Standards Update No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force) (ASU 2016-15). The amendments in ASU 2016-15 address eight specific cash flow issues and apply to all entities that are required to present a statement of cash flows under ASC Topic 230, Statement of Cash Flows. The amendments in ASU 2016-15 are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption during an interim period. The Company has not yet completed the analysis of how adopting this guidance will affect its consolidated financial statements.   In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for the Company on January 1, 2018; however, early adoption is permitted with prospective application to any business development transaction.   In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation: Scope of Modification Accounting, which provides clarification on when modification accounting should be used for changes to the terms or conditions of a share-based payment award. This ASU does not change the accounting for modifications but clarifies that modification accounting guidance should only be applied if there is a change to the value, vesting conditions or award classification and would not be required if the changes are considered non-substantive. The amendments of this ASU are effective for the Company in the first quarter of 2018, with early adoption permitted. The adoption of ASU 2017-09 is not expected to have an impact on the Companys consolidated financial statements.   There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Companys financial position, results of operations or cash flows. Inventory consists of raw materials, packaging components, work-in-process and finished goods. The Companys inventory is stated at the lower of cost (FIFO cost basis) or market. The carrying value of inventory consisted of the following at June 30, 2017 and December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt"> June 30, 2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">December 31, 2016</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Raw materials</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 11%; text-align: right">74,678</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">68,047</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Packaging components</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">97,782</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">84,927</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Work-in-process</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">23,461</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">17,406</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Finished goods</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">195,921</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">170,380</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Reserve for obsolescence</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(91,932</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(89,095</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Total inventory</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">103,989</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">81,285</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> As of June 30, 2017 and December 31, 2016 prepaid expenses and other assets consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt"> June 30, 2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">December 31, 2016</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Prepaid consulting services</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">1,011,155</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">150,168</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Prepaid clinical study</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">642,500</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Prepaid insurance</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">19,270</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">42,785</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Other Receivables</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">10,178</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">10,948</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Prepaid inventory</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">6,927</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">13,178</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Prepaid expenses</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">5,900</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">6,800</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Property and Equipment, net</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">1,695,930</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">223,879</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> As of June 30, 2017 and December 31, 2016 property and equipment and intangible assets consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt"> June 30, 2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt"> December 31, 2016</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Manufacturing equipment</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">769,074</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">769,074</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Computer and other equipment</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">147,192</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">116,747</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Leasehold improvements</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">36,066</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">36,066</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Less accumulated depreciation</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(627,681</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(551,239</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Property and Equipment, net</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">324,651</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">370,648</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>    Depreciation expense for the three and six months ended June 30, 2017 was $37,437 and $76,442, respectively, which includes depreciation of $2,160 and $4,320 for capitalized leased assets for the three and six months ended June 30, 2017, respectively. Depreciation expense for the three and six months ended June 30, 2016 was $26,507 and $54,062, respectively, which includes depreciation of $2,160 and $4,320 for capitalized leased assets for the three and six months ended June 30, 2016, respectively. The total amount of property held under a under a capital lease was $43,201 as of June 30, 2017 and December 31, 2016. Accumulated depreciation for property held under capital leases were $32,857 and $28,537 as of June 30, 2017 and December 31, 2016 respectively.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt"> June 30, 2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">December 31, 2016</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Intellectual Property</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">814,582</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">814,582</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Patents</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">191,602</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">175,047</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Less accumulated amortization</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(116,839</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(95,119</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Intangible assets, net</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">889,345</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">894,510</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   The Company incurred $16,555 and $45,930 of legal patent costs that were capitalized during the six months ended June 30, 2017 and the year ended December 31, 2016, respectively. The Company did not write off any intangibles during the six months ended June 30, 2017 and wrote off $58,522 of intangibles during the year ended December 31, 2016. Amortization expense for the three and six months ended June 30, 2017 was $10,821 and $21,720, respectively. Amortization expense for the three and six months ended June 30, 2016 was $10,667 and $21,332, respectively.   The estimated aggregate amortization expense over each of the next five years is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">2017</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">21,798</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">2018</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">43,518</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">2019</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">43,518</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">2020</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">43,518</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">2021</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">43,518</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Thereafter</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">557,303</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Total Amortization</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">753,172</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   Loan payable consist of the following at June 30, 2017 and December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2016</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Note to a company due September 29, 2017 including interest at 13.25% per annum; unsecured; interest due monthly</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; width: 9%; text-align: right">11,460</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; width: 9%; text-align: right">33,277</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Current portion of loan payable</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">11,460</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">33,277</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Loan payable, less current portion</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> Notes payable consist of the following at June 30, 2017 and December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2016</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Note to a company due August 27, 2017, no interest shall accrue unless and until an event of default occurs, where interest at 10% per annum shall accrue beginning on the date of the applicable event of default, secured by the Companys intellectual property</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">650,000</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Note to an individual, non-interest bearing, unsecured and has no fixed terms of repayment</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">50,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">50,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">700,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">50,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Unamortized discount</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(4,750</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Current portion of loan payable</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">695,250</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">50,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Loan payable, less current portion</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   During the three and six months ended June 30, 2017, the Company incurred $5,250 amortization of discount. During the three and six months ended June 30, 2016, the Company incurred $0 amortization of discount. Convertible promissory notes consist of the following at June 30, 2017 and December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2016</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Convertible promissory notes totaling $700,000 due between November 11, 2017 and December 30, 2017, interest payable at 8% per annum; unsecured; principal and accrued interest convertible into common stock at the lower of $7.00 per share or the price per share of the latest closing of a debt or equity offering by the Company greater than $3,000,000; accrued interest due between November 11, 2017 and December 30, 2017</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">700,000</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">700,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Unamortized discount</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(599,063</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Current portion of convertible promissory notes</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">100,937</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Convertible promissory notes, less current portion</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   During the three and six months ended June 30, 2017, the Company incurred $77,683 amortization of discount. During the three and six months ended June 30, 2016, the Company incurred $0 amortization of discount. During the three and six months ended June 30, 2017, the Company incurred $3,306 interest expenses and accrued interest as of June 30, 2017. During the three and six months ended June 30, 2016, the Company incurred $0 interest expenses and accrued interest as of June 30, 2016. The following table summarizes fair value measurements by level at June 30, 2017 for assets and liabilities measured at fair value on a recurring basis:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Level I</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Level II</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Level III</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Total</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Cash</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">277,961</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">277,961</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Derivative liability</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">(412,777</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">(412,777</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> </table>   No financial assets or liabilities were measured on a recurring basis as of December 31, 2016.   The Company has issued convertible promissory notes during 2017. The convertible notes require us to record the value of the conversion feature as a liability, at fair value, pursuant to ASC 815, including provisions in the notes that protect the holders from declines in the Companys stock price, which is considered outside the control of the Company. The derivative liabilities are marked-to-market each reporting period and changes in fair value are recorded as a non-operating gain or loss in our statement of operations, until they are completely settled. The fair value of the conversion feature is determined each reporting period using the Black-Scholes option pricing model, and is affected by changes in inputs to that model including our stock price, expected stock price volatility, interest rates and expected term. The assumptions used in valuing the derivative liability during 2017 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="width: 1%; text-align: justify"> </td> <td style="width: 12%; border-bottom-style: solid; border-bottom-width: 1pt"> June 30, 2017</td> <td style="width: 1%; text-align: justify"> </td></tr> <tr> <td style="vertical-align: top; text-align: justify">Significant assumptions (weighted-average):</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Risk-free interest rate at grant date</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">1.89%</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Expected stock price volatility</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">79.92%</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Expected dividend payout</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Expected option life (in years)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">1</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Expected forfeiture rate</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">0%</td> <td style="vertical-align: bottom"> </td></tr> </table>   The following is a reconciliation of the derivative liability for 2017:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt"> June 30, 2017</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Value at December 31, 2016</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Initial value at the debt issuance</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">370,232</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Increase in value</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">42,545</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Value at June 30, 2017</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">412,777</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> On January 3, 2017, the Company issued 1,300,000 warrants in connection with commissions earned in relation to the Companys Private Label Exclusive Distribution and License agreement with Red Barn Pet Products, LLC.   From May 11, 2017 to June 30, 2017, the Company issued 140,000 warrants in connection with the issuance of $700,000 convertible promissory notes.   Warrants that vest at the end of a one-year period are amortized over the vesting period using the straight-line method.   The Companys warrant activity was as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Warrants</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt"> Weighted Average Exercise Price</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Weighted Average Contractual Remaining Life</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Outstanding, December 31, 2016</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">4,392,107</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">1.97</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">6.17</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Granted</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">1,440,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">2.49</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">0.75</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Exercised</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Forfeited/Expired</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Outstanding, June 30, 2017</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">5,832,107</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">2.10</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">5.92</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Exercisable at June 30, 2017</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">3,6630,665</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">2.19</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">2.95</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>    <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">   Range of Exercise Price</td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt"> Number of Warrants</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Weighted Average Remaining Contractual Life (years)</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Weighted Average Exercise Price</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Number of Warrants Exercisable</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Weighted Average Exercise Price</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 20%; border-bottom: black 1pt solid; text-align: center">$1.00 - $7.00</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; width: 13%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">5,832,107</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; width: 13%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">5.92</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify">$</td> <td style="vertical-align: bottom; width: 13%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">2.10</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; width: 13%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">3,630,665</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify">$</td> <td style="vertical-align: bottom; width: 13%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">2.19</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">5,832,107</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">5.92</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">2.10</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">3,630,665</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">2.19</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   The weighted-average fair value of warrants granted to during the three months ended June 30, 2017 and year ended December 31, 2016, and the weighted-average significant assumptions used to determine those fair values, using a Black-Scholes-Merton (Black-Scholes) option pricing model are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt"> June 30, 2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt"> December 31, 2016</td> <td style="text-align: justify"> </td></tr> <tr> <td style="vertical-align: top; text-align: justify">Significant assumptions (weighted-average):</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Risk-free interest rate at grant date</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 11%; text-align: right">1.89</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">%</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 11%; text-align: right">1.83</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">%</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Expected stock price volatility</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">79.92</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">84.42</td> <td style="vertical-align: bottom; text-align: justify">%</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Expected dividend payout</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Expected option life (in years)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">3</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">3</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Expected forfeiture rate</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom; text-align: justify">%</td></tr> </table> Authorized Stock   The Company has authorized to issue is 75,000,000 common shares with a par value of $0.001 per share.   As of June 30, 2017 and December 31, 2016, there were 23,751,252 and 23,336,673, shares of the Companys common stock issued and outstanding, respectively.   Common Share Issuances   On April 7, 2017, the Company issued 14,579 common stock shares at $6.86 per share for consulting services to be performed over a one year period. The total value of this issuance was $100,000 and as of June 30, 2017, $76,986 is included in prepaid expenses and other assets.   On April 24, 2017, the Company issued 100,000 common stock shares at $7.00 per share for consulting services to be performed over a six month period. The total value of this issuance was $700,000 and as of June 30, 2017, $443,716 is included in prepaid expenses and other assets.   On May 18, 2017, the Company issued 300,000 common stock shares at $2.10 per share for consulting services to be performed over a one year period. The total value of this issuance was $630,000 and as of June 30, 2017, $357,288 is included in prepaid expenses and other assets. Litigation:   From time to time the Company may become a party to litigation in the normal course of business. Management believes that there are no current legal matters that would have a material effect on the Companys financial position or results of operations.    Operating leases   The Company maintains its corporate offices and manufacturing facility at 1620 Beacon Place, Oxnard, CA 93033, which contains approximately 25,000 square feet. The Company is currently on a month-to-month lease.   The Company also leases additional office and warehouse space at 1610 and 1612 Fiske Place, Oxnard, CA 93033, which contains approximately 6,547 square feet. The Company is currently on a month-to-month lease.   Total rent expense for the three and six month periods ended June 30, 2017 was $73,416 and $145,815, respectively. Total rent expense for the three and six month periods ended June 30, 2016 was $72,101 and $142,569, respectively. From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. The only significant matter of which the Company is aware of is discussed below.   On May 22, 2017, Sandy Sierra Garate (Applicant), an employee of the Company, filed an application for benefits due to serious and willful misconduct of the employer pursuant to labor code section 4553 with the State of California Workers Compensation Appeals Board (WCAB Case No: ADJ 10686812) resulting in injury arising out of and in the course of the Applicants employment on August 5, 2016. The Applicant is requesting relief in this matter for a one half increase in all compensation recoverable in connection with the injury of August 5, 2016, for the allowance of costs and expenses in an amount to be determined and for such further relief as in deemed appropriate. The Company is currently unable to determine what the additional expenses will be incurred in order to defend this matter. As such, the Company cannot determine whether there is a reasonable possibility that a loss will be incurred nor can it estimate the range of any such potential loss. Accordingly, the Company has not accrued an amount for any potential loss associated with this action. On July 19, 2017, the Company entered into a Development Agreement (Agreement) with Aveneon Technology, Ltd (Aveneon) for the development and formulation of certain active ingredients utilizing our proprietary CureFilm technology. In consideration of the development activities specified hereunder, Aveneon paid the Company a non-refundable and non-creditable fee of $35,692 (the Initial Fee) within one (1) day of the Effective Date. Aveneon shall pay the Company the following non-refundable and non-creditable milestone payment of $35,692 (the Milestone Payment) within fifteen (15) days after initiation of Phase IV Product Conformance.   On July 27, 2017, the Company received $300,000 by issuing a convertible promissory note (Convertible Note) to an individual that is due January 27, 2018 (Maturity Date). The Convertible Note shall accrue interest at 8% per annum and is unsecured. The conversion price of the Common Stock into which the Principal Amount, or the then outstanding interest due thereon, shall be the lower of $7.00 or the price per share of the latest closing of a debt or equity offering by the Company greater than $3,000,000. Pursuant to issuing this Convertible Note, the Company issued to the holder of this Convertible Note a warrant to purchase 60,000 shares of Common Stock at an exercise price at the lower of $7.00 per share or the price per share of the latest closing of a debt or equity offering by the Company greater than $3,000,000.   In July 2017 the Company, Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company dedicated to the development of cannabinoid-based drugs headquartered in Israel, and Assuta Medical Centers, Ltd., a medical services center located in Israel, entered into a nonbinding memorandum of understanding to collaborate to advance, research, develop and commercialize potential therapeutic products in the fields of personalized medicine and cannabinoids. The Company has not entered into any binding agreements or advanced any funds in connection with the foregoing. The condensed consolidated financial statements include the accounts of Cure Pharmaceutical Holding Corp (CPHC) and its wholly-owned subsidiary, Cure Pharmaceutical Corporation (Cure), collectively referred to as (Cure, we, us, our or the Company All significant inter-company balances and transactions have been eliminated in consolidation. The Companys film strip product represents the principal operations of the Company.   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (SEC). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Companys management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2017, and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2017 and 2016, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in Form 10-K for the fiscal period ended December 31, 2016 filed with the Securities and Exchange Commission (the SEC) on April 17, 2017. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. These estimates and assumptions also affect the reported amounts of revenues, costs and expenses during the reporting period. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates. The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents. As of June 30, 2017 and December 31, 2016, the Company had no cash equivalents. At June 30, 2017 and December 31, 2016, the Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. An associate is an entity over which the Company has significant influence through a joint venture. Significant influence is the power to participate in the financial and operating policy decisions of the investee but not control or joint control over those policies.   The results of assets and liabilities of associates are incorporated in the condensed consolidated financial statements using the equity method of accounting. Under the equity method, investments in associates are carried in the consolidated balance sheet at cost as adjusted for post-acquisition changes in the Companys share of the net assets of the associate, less any impairment in the value of the investment. Losses of an associate in excess of the Companys interest in that associate are not recognized. Additional losses are provided for, and a liability is recognized, only to the extent that the Company has incurred legal or constructive obligations or made payments on behalf of the associate.   Any excess of the cost of acquisition over the Companys share of the net fair value of the identifiable assets, liabilities and contingent liabilities of the associate recognized at the date of acquisition is recognized as goodwill. The goodwill is included within the carrying amount of the investment.   On January 8, 2016, the Company received 50% ownership in Cure Innovations, Inc (CI). CI was created in 2015 by IncuBrands Studio, Inc (IncuBrands). The Company and IncuBrands each own 50% of the common stock of CI. The Company and IncuBrands entered into a Joint Venture agreement in 2013 to distribute several OTF products utilizing IncuBrands marketing and contacts in various industries as well as utilize the Companys technology and capabilities of manufacturing OTFs.   On December 6, 2016, the Company entered into a Joint Venture Agreement (Joint Venture) with Pace Wellness, Inc. (Pace) to jointly develop three Active Pharmaceutical Ingredients (API) within the nonprescription and/or Over-the-Counter (OTC) medicines specifically utilizing the Companys patented and proprietary CureFilm Technology. The three APIs to be jointly developed are Diphenhydramine HCL, Omeprazole and a third API to be determined at a later date (Products). Pace shall be the exclusive global distributor of the Products under the Solves Strips® branding or other private or branded labels. All benefits, advantages, and liabilities derived from, or incurred in respect of the Joint Venture shall be borne by the parties in proportion of their respective participating interests of 50/50 equal interest. The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred. Depreciation has been provided using the straight-line method on the following estimated useful lives:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 61%; text-align: justify">Manufacturing equipment</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 37%; text-align: center">5-7 Years</td> <td style="width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; text-align: justify">Computer and other equipment</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">3-7 Years</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Leasehold Improvements</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">Lesser of useful life or the term of the lease</td> <td> </td></tr> </table> Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and managements evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts. Long-lived assets include equipment and intangible assets other than those with indefinite lives. We assess the carrying value of our long-lived asset groups when indicators of impairment exist and recognize an impairment loss when the carrying amount of a long-lived asset is not recoverable when compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset.   Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the fair value of the asset (or asset group), typically a discounted cash flow analysis, and an impairment charge is recorded for the excess of carrying value over fair value. There were no impairments on our long-lived assets during the three and six month periods ended June 30, 2017 and 2016. The Company recognizes revenue in accordance with the FASB ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Company believes that these criteria are satisfied upon shipment from our facility. Freight billed to customers is presented as revenues, and the related freight costs are presented as cost of goods sold. Deferred revenue is recognized when earned and all significant obligations have been satisfied. The Company expenses marketing, promotions and advertising costs as incurred. Such costs are included in general and administrative expense in the accompanying statements of operations. The Company recorded advertising costs of $68,893 and $95,226, for the three and six month periods ended June 30, 2017, respectively, and none for the three and six month periods ended June 30, 2016. Costs incurred in connection with the development of new products and processes are charged to research and development expenses as incurred. The Company utilizes FASB ASC 740, Income Taxes, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is more likely-than-not that a deferred tax asset will not be realized.    The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of the Companys realization of the net operating loss carry forward prior to its expiration. Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.   Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the measurement date. The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date. The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.   The estimated fair value of certain financial instruments, including cash and cash equivalents are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.   ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:   Level 1 quoted prices in active markets for identical assets or liabilities Level 2 quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 inputs that are unobservable (for example cash flow modeling inputs based on assumptions)   The Company has assets or liabilities valued at fair value on a recurring basis for the six months ended June 30, 2017. The Company did not have assets or liabilities valued at fair value on a recurring basis for the year ended December 31, 2016. Basic loss per share is computed by dividing the net loss to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the net loss for the period by the weighted average number of common and dilutive common equivalent shares outstanding during the period. Common equivalent shares, which consist of stock options, warrants, and convertible notes payable, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. The Companys financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit at June 30, 2017 of $15,880,139. The Company had a working capital of $221,888 as of June 30, 2017. These factors raise substantial doubt about the Companys ability to continue as a going concern for one year from the issuance of the financial statements. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. The Company is continually analyzing its current costs and is attempting to make additional cost reductions where possible. We expect that we will continue to generate losses from operations throughout 2017.    In order to continue as a going concern and to develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Managements plans to continue as a going concern include raising additional capital through borrowing and/or sales of equity and debt securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.   The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The purpose is to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information. This ASU is effective for the Company in the first quarter of 2018. Early adoption is not permitted except for limited provisions. The Company does not expect the adoption of this amendment to have a material effect on its financial condition and results of operations.   In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This new standard became effective for the Company on January 1, 2017. The adoption of this standard did not have a material impact on its financial position, results of operations or statements of cash flows upon adoption.   In August, 2016, the FASB issued Accounting Standards Update No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force) (ASU 2016-15). The amendments in ASU 2016-15 address eight specific cash flow issues and apply to all entities that are required to present a statement of cash flows under ASC Topic 230, Statement of Cash Flows. The amendments in ASU 2016-15 are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption during an interim period. The Company has not yet completed the analysis of how adopting this guidance will affect its consolidated financial statements.   In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for the Company on January 1, 2018; however, early adoption is permitted with prospective application to any business development transaction.   In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation: Scope of Modification Accounting, which provides clarification on when modification accounting should be used for changes to the terms or conditions of a share-based payment award. This ASU does not change the accounting for modifications but clarifies that modification accounting guidance should only be applied if there is a change to the value, vesting conditions or award classification and would not be required if the changes are considered non-substantive. The amendments of this ASU are effective for the Company in the first quarter of 2018, with early adoption permitted. The adoption of ASU 2017-09 is not expected to have an impact on the Companys consolidated financial statements.   There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Companys financial position, results of operations or cash flows. <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt">June 30, 2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">December 31, 2016</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Prepaid consulting services</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">1,011,155</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">150,168</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Prepaid clinical study</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">642,500</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Prepaid insurance</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">19,270</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">42,785</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Other Receivables</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">10,178</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">10,948</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Prepaid inventory</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">6,927</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">13,178</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Prepaid expenses</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">5,900</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">6,800</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Property and Equipment, net</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">1,695,930</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">223,879</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt">June 30, 2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">December 31, 2016</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Manufacturing equipment</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">769,074</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">769,074</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Computer and other equipment</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">147,192</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">116,747</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Leasehold improvements</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">36,066</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">36,066</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Less accumulated depreciation</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(627,681</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(551,239</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Property and Equipment, net</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">324,651</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">370,648</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt">June 30, 2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">December 31, 2016</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Intellectual Property</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">814,582</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">814,582</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Patents</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">191,602</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">175,047</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Less accumulated amortization</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(116,839</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(95,119</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Intangible assets, net</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">889,345</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">894,510</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> The estimated aggregate amortization expense over each of the next five years is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">2017</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 11%; text-align: right">21,798</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">2018</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">43,518</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">2019</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">43,518</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">2020</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">43,518</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">2021</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">43,518</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Thereafter</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">557,303</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 8.05pt; text-align: justify">Total Amortization</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">753,172</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2017</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2016</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Convertible promissory notes totaling $700,000 due between November 11, 2017 and December 30, 2017, interest payable at 8% per annum; unsecured; principal and accrued interest convertible into common stock at the lower of $7.00 per share or the price per share of the latest closing of a debt or equity offering by the Company greater than $3,000,000; accrued interest due between November 11, 2017 and December 30, 2017</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">700,000</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">700,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Unamortized discount</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(599,063</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Current portion of convertible promissory notes</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">100,937</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Convertible promissory notes, less current portion</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="width: 1%; text-align: justify"> </td> <td style="width: 12%; border-bottom-style: solid; border-bottom-width: 1pt">June 30, 2017</td> <td style="width: 1%; text-align: justify"> </td></tr> <tr> <td style="vertical-align: top; text-align: justify">Significant assumptions (weighted-average):</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Risk-free interest rate at grant date</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">1.89%</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Expected stock price volatility</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">79.92%</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Expected dividend payout</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Expected option life (in years)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">1</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Expected forfeiture rate</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">0%</td> <td style="vertical-align: bottom"> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Level I</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Level II</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Level III</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Total</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Cash</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">277,961</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">277,961</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Derivative liability</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">(412,777</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">(412,777</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt">June 30, 2017</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Value at December 31, 2016</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 11%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Initial value at the debt issuance</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">370,232</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Increase in value</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">42,545</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Value at June 30, 2017</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 1.5pt; text-align: right">412,777</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> 642500 81285 103989 -89095 -91932 170380 195921 17406 23461 84927 97782 68047 74678 150168 1011155 642500 42785 19270 10948 10178 13178 6927 6800 5900 -95119 -116839 894510 889345 21798 43518 43518 43518 43518 557303 753172 116747 769074 36066 769074 147192 36066 551239 627681 370648 324651 814582 175047 814582 191602 76442 54062 37437 26507 2160 4320 2160 4320 43201 43201 32857 28537 45930 16555 58522 21720 21332 10821 10667 700000 700000 -599063 100937 77683 0 77683 0 3306 0 3306 0 3306 0 3306 0 33277 11640 0.1325 2017-09-29 2018-01-27 50000 700000 650000 50000 50000 50000 695250 0.0189 0.0183 0.0189 0.7992 0.8442 0.7992 P1Y P3Y P3Y 0.00 0.00 0.00 370232 42545 5832107 4392107 5832107 5832107 3630665 3630665 3630665 2.10 1.97 2.10 2.10 2.19 2.19 2.19 P5Y11M1D P5Y11M1D P6Y2M1D 1.00 7.00 1300000 140000 76986 443716 357288 630000 700000 100000 145815 142569 73416 72101 35692 35692 300000 0.08 The conversion price of the Common Stock into which the Principal Amount, or the then outstanding interest due thereon, shall be the lower of $7.00 or the price per share of the latest closing of a debt or equity offering by the Company greater than $3,000,000. 60000 -4750 5250 0 5250 0 42545 42545 223879 1695930 412777 1440000 2.49 P0Y9M0D P5Y11M1D P2Y11M1D 700000 25000 6547 EX-101.SCH 7 curr-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - PREPAID EXPENSES AND OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - LOAN PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - CONVERTIBLE PROMISSORY NOTES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - DERIVATIVE LIABILITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - WARRANT AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - LEGAL PROCEEDINGS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - PREPAID EXPENSES AND OTHER ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - LOAN PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - DERIVATIVE LIABILITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - WARRANT AGREEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - PREPAID EXPENSES AND OTHER ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - LOAN PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - LOAN PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - DERIVATIVE LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - DERIVATIVE LIABILITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - DERIVATIVE LIABILITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - WARRANT AGREEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - WARRANT AGREEMENTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - WARRANT AGREEMENTS (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - WARRANT AGREEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 curr-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 curr-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 curr-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Leasehold Improvements [Member] Property, Plant and Equipment, Type [Axis] Manufacturing Equipment [Member] Maximum [Member] Range [Axis] Computer and other equipment [Member] Minimum [Member] Intellectual Property [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Convertible Promissory Notes [Member] Short-term Debt, Type [Axis] Warrant [Member] Equity Components [Axis] Loans Payable [Member] Underlying Asset Class [Axis] License agreement [Member] Legal Entity [Axis] TRDF [Member] Income Statement Location [Axis] Manufacturing equipmentt [Member] Collateral [Axis] Depreciation on capitalized leased [Member] Assets Held under Capital Leases [Member] Company [Member] Individual Counterparty [Member] Legal Entity of Counterparty, Type [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] $1.00 - $7.00 [Member] Exercise Price Range [Axis] Common Stock [Member] Prepaid Expenses And Other Assets [Member] Prepaid Expenses And Other Assets One [Member] Prepaid Expenses And Other Assets Two [Member] Subsequent Event [Member] Subsequent Event Type [Axis] Milestone Payment [Member] Transaction Type [Axis] Offices And Manufacturing Facility [Member] Office And Warehouse Space [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets: Cash Accounts receivable Inventory Prepaid expenses and other assets Total current assets Property and equipment, net Intellectual property and patents, net Other assets Total assets Liabilities and Stockholders' Equity Current liabilities: Accounts payable Accrued expenses Loan payable Note payable, net of unamortized discount Capital lease payable Convertible promissory notes, net of unamortized discount Derivative liability Deferred revenue Total current liabilities License Fees TOTAL LIABILITIES Stockholders' equity: Common stock: $0.001 par value; authorized 75,000,000 shares; 23,751,252 and 23,336,673 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity STOCKHOLDERS' DEFICIT Common Stock, Par Value Per Share Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding Condensed Consolidated Statements Of Operations REVENUE Net product sales Consulting research & development income Shipping and other sales Total revenues Cost of goods sold Gross profit (loss) Research and development expenses Selling, general and administrative expenses Total costs and expenses Net loss from operations Other income (expense): Interest income Other income Loss on disposal of PP&E Change in derivative liability Other expense Interest expense Other income (expense) Net loss before income taxes Provision for income taxes Net loss Net loss per share, basic and diluted Weighted average shares outstanding, basic and diluted Statement of Cash Flows [Abstract] Cash Flows from Operating Activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Loss from joint venture Loss on disposal of PP&E Amortization of prepaid stock –based compensation Amortization of loan discounts Change in derivative liabilities Warrants issued for services Change in other assets and liabilities: Restricted cash Accounts receivable Inventory Prepaid expenses and other assets Other assets Accounts payable Accrued expenses Deferred revenue Net cash used in operating activities Cash flows from investing activities: Advanced on note receivable Purchase in intangible assets Payment to joint venture investment Acquisition of property and equipment, net Net cash used in investing activities Cash flows from financing activities: Proceeds from loan Loan repayments Capital lease payments Net cash provided by financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Supplemental cash flow information: Cash paid for Interest Cash paid for Income taxes Non-cash financing activities: Common stock to be issued for prepaid expense Loan discount relating to note payable Loan discount relating to convertible promissory notes Notes to Financial Statements Note 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS Note 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Note 3 - Inventory Note 4 - PREPAID EXPENSES AND OTHER ASSETS Note 5 - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS Note 6 - LOAN PAYABLE Note 7 - NOTES PAYABLE Note 8 - CONVERTIBLE PROMISSORY NOTES Note 9 - DERIVATIVE LIABILITY Note 10 - Warrant Agreements Note 11 - Stockholders' Equity Note 12 - Commitments and Contingencies Note 13 - LEGAL PROCEEDINGS Note 14 - SUBSEQUENT EVENTS Summary Of Significant Accounting Policies Policies Principles of consolidation and basis of presentation Use of Estimates Cash and Cash Equivalents Investment in Associates Property and Equipment Accounts receivable Impairment of Long-Lived Assets Revenue Recognition Advertising Expense Research and Development Income Taxes Stock-Based Compensation Fair Value Measurements Basic and diluted loss per share Going Concern Recently Issued Standards Summary Of Significant Accounting Policies Tables Property and equipment Inventory Tables Inventory Of Carrying Value Prepaid Expenses And Other Assets Tables Prepaid expenses and other assets Property And Equipment And Intangible Assets Tables Property and equipment and intangible assets Intangible assets, net Amortization expense Loan Payable Tables Loan Payable Notes Payable Tables Notes Payable Convertible Promissory Notes Tables Convertible promissory Derivative Liability Tables Derivative liability Derivative liability assumptions used Reconciliation of the derivative liability Warrant Agreements Tables Company stock option activity Weighted Average fair value of warrants granted Statement [Table] Statement [Line Items] State of Incorporation Date of Incorporation Payment of research project Estimated useful lives Estimated useful lives description Summary Of Significant Accounting Policies Details Narrative Federal deposit insurance corporation Ownership interest Advertising Expense Valuation allowance percentage Working capital deficit Inventory Details Raw Materials Packaging Components Work-In-Process Finished Goods Inventory, Gross Reserve for Obsolescence Total inventory Prepaid Expenses And Other Assets Details Prepaid consulting services Prepaid clinical study Prepaid insurance Other Receivables Prepaid inventory Prepaid expenses Property and Equipment, net Property and Equipment Less accumulated depreciation Property and Equipment, net Intellectual Property Less accumulated amortization Intangible assets, net Property And Equipment And Intangible Assets Details 2 2017 2018 2019 2020 2021 Thereafter Total Amortization Depreciation expense Capital lease Accumulated depreciation Patent costs capitalized Wrote off intangible Amortization expense Current portion of loan payable Loan payable, less current portion Interest rate Maturity date Total notes payable Unamortized discount Current portion of loan payable Notes Payable Details Narrative Amortization of discount Total Convertible promissory notes Unamortized discount Current portion of convertible promissory notes Convertible promissory notes, less current portion Convertible Promissory Notes Details Narrative Amortization of discount Accrued interest Interest expenses Derivative liability Derivative Liability Details 1 Significant assumptions (weighted-average): Risk-free interest rate at grant date Expected stock price volatility Expected dividend payout Expected option life (in years) Expected forfeiture rate Derivative Liability Details 2 Value at December 31, 2016 Initial value at the debt issuance Increase in value Value at June 30, 2017 Warratns Outstanding, December 31, 2016 Granted Exercised Forfeited/Expired Outstanding, June 30, 2017 Exercisable at June 30, 2017 Weighted Average Exercise Price Outstanding, December 31, 2016 Granted Exercised Forfeited/Expired Outstanding, June 30, 2017 Exercisable at June 30, 2017 Weighted Average Contractual Remaining Life Outstanding, December 31, 2016 Granted Outstanding, June 30, 2017 Exercisable at June 30, 2017 Range of Exercise Price Lower Limit Range of Exercise Price Upper Limited Number of Warrants Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number of Warrants Exercisable Weighted Average Exercise Price Warrants granted Issuance of convertible promissory note Common stock, par value per share Common stock, shares authorized Common stock, shares issued Common share issuances value Offices and manufacturing facility area Total rent expense Non-refundable fee Proceeds from convertible promissory note Interest rate Note conversion description Warrant to purchase common shares Disclosure of accounting policy for revenue recognition. Loss from joint venture. Warrants granted. Assets, Current Assets [Default Label] Derivative Liability Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Other Nonoperating Expense Interest Expense LossFromJointVenture Gain (Loss) on Disposition of Property Plant Equipment Increase (Decrease) in Restricted Cash Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Increase (Decrease) in Other Operating Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Deferred Revenue Net Cash Provided by (Used in) Operating Activities Payments to Acquire Notes Receivable Payments to Acquire Intangible Assets Payments to Acquire Equity Method Investments Payments to Acquire Machinery and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Debt Repayments of Debt and Capital Lease Obligations Net Cash Provided by (Used in) Financing Activities Cash, Period Increase (Decrease) Receivables, Policy [Policy Text Block] Schedule of Other Assets [Table Text Block] Advertising Expense [Default Label] Property, Plant and Equipment, Gross Sale Leaseback Transaction, Accumulated Depreciation Other Intangible Assets, Net Deferred Policy Acquisition Cost, Amortization Expense Notes and Loans Payable Debt Instrument, Unamortized Discount Amortization of Debt Discount (Premium) Derivative Liability, Fair Value, Gross Liability Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted Debt Conversion, Original Debt, Interest Rate of Debt EX-101.PRE 11 curr-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1

Document and Entity Information - shares
6 Months Ended

Jun. 30, 2017

Aug. 10, 2017

Document And Entity Information

Entity Registrant Name CURE PHARMACEUTICAL HOLDING CORP.

Entity Central Index Key 0001643301

Document Type 10-Q

Document Period End Date Jun. 30, 2017

Amendment Flag false

Current Fiscal Year End Date --12-31

Is Entity a Well-known Seasoned Issuer? No

Is Entity a Voluntary Filer? No

Is Entity's Reporting Status Current? Yes

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 23,751,252

Document Fiscal Period Focus Q2

Document Fiscal Year Focus 2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash	$ 277,961	$ 1,106,142
Accounts receivable	13,443	7,049
Inventory	103,989	81,285
Prepaid expenses and other assets	1,695,930	223,879
Total current assets	2,091,323	1,418,355
Property and equipment, net	324,651	370,648
Intellectual property and patents, net	889,345	894,510
Other assets	133,878	151,579
Total assets	3,439,197	2,835,092
Current liabilities:
Accounts payable	416,736	265,386
Accrued expenses	36,441	26,305
Loan payable	11,460	33,277
Note payable, net of unamortized discount	695,250	50,000
Capital lease payable	3,234	9,453
Convertible promissory notes, net of unamortized discount	100,937
Derivative liability	412,777
Deferred revenue	192,600	173,618
Total current liabilities	1,869,435	558,039
License Fees	560,000	560,000
TOTAL LIABILITIES	2,429,435	1,118,039
Stockholders' equity:
Common stock: $0.001 par value; authorized 75,000,000 shares; 23,751,252 and 23,336,673 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	23,752	23,337
Additional paid-in capital	16,866,149	12,412,430
Accumulated deficit	(15,880,139)	(10,718,714)
Total stockholders' equity	1,009,762	1,717,053
Total liabilities and stockholders' equity	$ 3,439,197	$ 2,835,092

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
STOCKHOLDERS' DEFICIT
Common Stock, Par Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	75,000,000	75,000,000
Common Stock, Shares Issued	23,751,252	23,336,673
Common Stock, Shares Outstanding	23,751,252	23,336,673

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
REVENUE
Net product sales	$ 32,073	$ 14,151	$ 59,570	$ 42,662
Consulting research & development income			4,448
Shipping and other sales	6,812	3,000	6,812	3,098
Total revenues	38,885	17,151	70,830	45,760
Cost of goods sold	39,598	10,579	75,148	37,744
Gross profit (loss)	(713)	6,572	(4,318)	8,016
Research and development expenses	205,648	171,447	425,268	298,799
Selling, general and administrative expenses	2,194,950	304,669	4,597,497	596,605
Total costs and expenses	2,400,598	476,116	5,022,765	895,404
Net loss from operations	(2,401,311)	(469,544)	(5,027,083)	(887,388)
Other income (expense):
Interest income	1	45	5	412
Other income	8,571	8,571	17,142	17,142
Loss on disposal of PP&E	(12,351)		(12,351)	(3,323)
Change in derivative liability	(42,545)		(42,545)
Other expense	(6,394)	(88,491)	(7,388)	(100,634)
Interest expense	(87,054)	(47,603)	(89,205)	(99,321)
Other income (expense)	(139,772)	(127,478)	(134,342)	(185,724)
Net loss before income taxes	(2,541,083)	(597,022)	(5,161,425)	(1,073,112)
Provision for income taxes
Net loss	$ (2,541,083)	$ (597,022)	$ (5,161,425)	$ (1,073,112)
Net loss per share, basic and diluted	$ (0.11)	$ (0.09)	$ (0.22)	$ (0.16)
Weighted average shares outstanding, basic and diluted	23,436,696	6,629,260	23,593,105	6,629,260

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash Flows from Operating Activities:
Net loss	$ (5,161,425)	$ (1,073,112)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	98,161	75,394
Loss from joint venture	5,488
Loss on disposal of PP&E	12,351	3,323
Amortization of prepaid stock –based compensation	552,010
Amortization of loan discounts	82,933
Change in derivative liabilities	42,545
Warrants issued for services	2,717,620
Change in other assets and liabilities:
Restricted cash		(50,000)
Accounts receivable	(6,394)	1,679
Inventory	(22,704)	12,975
Prepaid expenses and other assets	(594,061)	(703,838)
Other assets	17,213	8,858
Accounts payable	151,350	(265,682)
Accrued expenses	10,136	46,823
Deferred revenue	18,982	(28,539)
Net cash used in operating activities	(2,075,795)	(1,972,119)
Cash flows from investing activities:
Advanced on note receivable		(18,290)
Purchase in intangible assets	(16,555)	(25,527)
Payment to joint venture investment	(5,000)
Acquisition of property and equipment, net	(42,795)	(48,830)
Net cash used in investing activities	(64,350)	(92,647)
Cash flows from financing activities:
Proceeds from loan	1,340,000	4,371,963
Loan repayments	(21,817)	(289,253)
Capital lease payments	(6,219)	(5,509)
Net cash provided by financing activities	1,311,964	4,077,201
Net increase (decrease) in cash and cash equivalents	(828,181)	2,012,435
Cash and cash equivalents, beginning of period	1,106,142	13,352
Cash and cash equivalents, end of period	277,961	2,025,787
Supplemental cash flow information:
Cash paid for Interest	2,967	28,892
Cash paid for Income taxes
Non-cash financing activities:
Common stock to be issued for prepaid expense	1,430,000
Loan discount relating to note payable	10,000
Loan discount relating to convertible promissory notes	$ 676,746

XML 17 R6.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND DESCRIPTION OF BUSINESS

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Note 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

XML 18 R7.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Note 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Basis of Presentation

Use of Estimates

Cash and Cash Equivalents

Investment in Associates

Property and Equipment

Manufacturing equipment		5-7 Years
Computer and other equipment		3-7 Years
Leasehold Improvements		Lesser of useful life or the term of the lease

Accounts Receivable

Impairment of Long-Lived Assets

Revenue Recognition

Advertising Expense

Research and Development

Costs incurred in connection with the development of new products and processes are charged to research and development expenses as incurred.

Income Taxes

Stock-Based Compensation

Fair Value Measurements

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Basic and diluted loss per share

Going Concern

Recently Issued Standards

XML 19 R8.htm IDEA: XBRL DOCUMENT

INVENTORY

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Note 3 - Inventory

	June 30, 2017			December 31, 2016
Raw materials	$	74,678		$	68,047
Packaging components		97,782			84,927
Work-in-process		23,461			17,406
Finished goods		-			-
		195,921			170,380
Reserve for obsolescence		(91,932	)		(89,095	)
Total inventory	$	103,989		$	81,285

XML 20 R9.htm IDEA: XBRL DOCUMENT

PREPAID EXPENSES AND OTHER ASSETS

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Note 4 - PREPAID EXPENSES AND OTHER ASSETS

As of June 30, 2017 and December 31, 2016 prepaid expenses and other assets consisted of the following:

	June 30, 2017		December 31, 2016

Prepaid consulting services	$	1,011,155	$	150,168
Prepaid clinical study		642,500		-
Prepaid insurance		19,270		42,785
Other Receivables		10,178		10,948
Prepaid inventory		6,927		13,178
Prepaid expenses		5,900		6,800
Property and Equipment, net	$	1,695,930	$	223,879

XML 21 R10.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Note 5 - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS

As of June 30, 2017 and December 31, 2016 property and equipment and intangible assets consisted of the following:

	June 30, 2017			December 31, 2016

Manufacturing equipment	$	769,074		$	769,074
Computer and other equipment		147,192			116,747
Leasehold improvements		36,066			36,066
Less accumulated depreciation		(627,681	)		(551,239	)
Property and Equipment, net	$	324,651		$	370,648

	June 30, 2017			December 31, 2016

Intellectual Property	$	814,582		$	814,582
Patents		191,602			175,047
Less accumulated amortization		(116,839	)		(95,119	)
Intangible assets, net	$	889,345		$	894,510

The estimated aggregate amortization expense over each of the next five years is as follows:

2017	$	21,798
2018		43,518
2019		43,518
2020		43,518
2021		43,518
Thereafter		557,303
Total Amortization	$	753,172

XML 22 R11.htm IDEA: XBRL DOCUMENT

LOAN PAYABLE

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Note 6 - LOAN PAYABLE

Loan payable consist of the following at June 30, 2017 and December 31, 2016:

	2017		2016
Note to a company due September 29, 2017 including interest at 13.25% per annum; unsecured; interest due monthly	$	11,460	$	33,277
Current portion of loan payable		11,460		33,277
Loan payable, less current portion	$	-	$	-

XML 23 R12.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Note 7 - NOTES PAYABLE

Notes payable consist of the following at June 30, 2017 and December 31, 2016:

	2017			2016

Note to a company due August 27, 2017, no interest shall accrue unless and until an event of default occurs, where interest at 10% per annum shall accrue beginning on the date of the applicable event of default, secured by the Company’s intellectual property	$	650,000		$	-
Note to an individual, non-interest bearing, unsecured and has no fixed terms of repayment		50,000			50,000

		700,000			50,000
Unamortized discount		(4,750	)		-
Current portion of loan payable		695,250			50,000
Loan payable, less current portion	$	-		$	-

XML 24 R13.htm IDEA: XBRL DOCUMENT

CONVERTIBLE PROMISSORY NOTES

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Note 8 - CONVERTIBLE PROMISSORY NOTES

Convertible promissory notes consist of the following at June 30, 2017 and December 31, 2016:

	2017			2016

Convertible promissory notes totaling $700,000 due between November 11, 2017 and December 30, 2017, interest payable at 8% per annum; unsecured; principal and accrued interest convertible into common stock at the lower of $7.00 per share or the price per share of the latest closing of a debt or equity offering by the Company greater than $3,000,000; accrued interest due between November 11, 2017 and December 30, 2017	$	700,000		$	-

		700,000			-
Unamortized discount		(599,063	)		-
Current portion of convertible promissory notes		100,937			-
Convertible promissory notes, less current portion	$	-		$	-

XML 25 R14.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITY

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Note 9 - DERIVATIVE LIABILITY

The following table summarizes fair value measurements by level at June 30, 2017 for assets and liabilities measured at fair value on a recurring basis:

	Level I		Level II		Level III			Total
Cash	$	277,961	$	—	$	—		$	277,961

Derivative liability		—		—	$	(412,777	)	$	(412,777	)

No financial assets or liabilities were measured on a recurring basis as of December 31, 2016.

		June 30, 2017
Significant assumptions (weighted-average):
Risk-free interest rate at grant date		1.89%
Expected stock price volatility		79.92%
Expected dividend payout		-
Expected option life (in years)		1
Expected forfeiture rate		0%

The following is a reconciliation of the derivative liability for 2017:

	June 30, 2017
Value at December 31, 2016	$	-
Initial value at the debt issuance		370,232
Increase in value		42,545
Value at June 30, 2017	$	412,777

XML 26 R15.htm IDEA: XBRL DOCUMENT

WARRANT AGREEMENTS

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Note 10 - Warrant Agreements

From May 11, 2017 to June 30, 2017, the Company issued 140,000 warrants in connection with the issuance of $700,000 convertible promissory notes.

Warrants that vest at the end of a one-year period are amortized over the vesting period using the straight-line method.

The Company’s warrant activity was as follows:

	Warrants		Weighted Average Exercise Price		Weighted Average Contractual Remaining Life
Outstanding, December 31, 2016		4,392,107		1.97		6.17
Granted		1,440,000		2.49		0.75
Exercised		-		-		-
Forfeited/Expired		-		-		-
Outstanding, June 30, 2017		5,832,107		2.10		5.92
Exercisable at June 30, 2017		3,6630,665		2.19		2.95

Range of

Exercise Price

Number of

Warrants

Weighted Average Remaining Contractual Life (years)

Weighted Average Exercise Price

Number of Warrants Exercisable

Weighted Average Exercise Price

$1.00 - $7.00

5,832,107

5.92

2.10

3,630,665

2.19

5,832,107

5.92

2.10

3,630,665

2.19

	June 30, 2017			December 31, 2016
Significant assumptions (weighted-average):
Risk-free interest rate at grant date		1.89	%		1.83	%
Expected stock price volatility		79.92	%		84.42	%
Expected dividend payout		-			-
Expected option life (in years)		3			3
Expected forfeiture rate		0	%		0	%

XML 27 R16.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Note 11 - Stockholders' Equity

Authorized Stock

The Company has authorized to issue is 75,000,000 common shares with a par value of $0.001 per share.

As of June 30, 2017 and December 31, 2016, there were 23,751,252 and 23,336,673, shares of the Company’s common stock issued and outstanding, respectively.

Common Share Issuances

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Note 12 - Commitments and Contingencies

Litigation:

Operating leases

XML 29 R18.htm IDEA: XBRL DOCUMENT

LEGAL PROCEEDINGS

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Note 13 - LEGAL PROCEEDINGS

XML 30 R19.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Note 14 - SUBSEQUENT EVENTS

XML 31 R20.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2017

Summary Of Significant Accounting Policies Policies

Principles of consolidation and basis of presentation

Use of Estimates

Cash and Cash Equivalents

Investment in Associates

Property and Equipment

Manufacturing equipment		5-7 Years
Computer and other equipment		3-7 Years
Leasehold Improvements		Lesser of useful life or the term of the lease

Accounts receivable

Impairment of Long-Lived Assets

Revenue Recognition

Advertising Expense

Research and Development

Costs incurred in connection with the development of new products and processes are charged to research and development expenses as incurred.

Income Taxes

Stock-Based Compensation

Fair Value Measurements

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Basic and diluted loss per share

Going Concern

Recently Issued Standards

XML 32 R21.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2017

Summary Of Significant Accounting Policies Tables

Property and equipment

Manufacturing equipment		5-7 Years
Computer and other equipment		3-7 Years
Leasehold Improvements		Lesser of useful life or the term of the lease

XML 33 R22.htm IDEA: XBRL DOCUMENT

INVENTORY (Tables)

6 Months Ended

Jun. 30, 2017

Inventory Tables

Inventory Of Carrying Value

	June 30, 2017			December 31, 2016
Raw materials	$	74,678		$	68,047
Packaging components		97,782			84,927
Work-in-process		23,461			17,406
Finished goods		-			-
		195,921			170,380
Reserve for obsolescence		(91,932	)		(89,095	)
Total inventory	$	103,989		$	81,285

XML 34 R23.htm IDEA: XBRL DOCUMENT

PREPAID EXPENSES AND OTHER ASSETS (Tables)

6 Months Ended

Jun. 30, 2017

Prepaid Expenses And Other Assets Tables

Prepaid expenses and other assets

	June 30, 2017		December 31, 2016

Prepaid consulting services	$	1,011,155	$	150,168
Prepaid clinical study		642,500		-
Prepaid insurance		19,270		42,785
Other Receivables		10,178		10,948
Prepaid inventory		6,927		13,178
Prepaid expenses		5,900		6,800
Property and Equipment, net	$	1,695,930	$	223,879

XML 35 R24.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2017

Property And Equipment And Intangible Assets Tables

Property and equipment and intangible assets

	June 30, 2017			December 31, 2016

Manufacturing equipment	$	769,074		$	769,074
Computer and other equipment		147,192			116,747
Leasehold improvements		36,066			36,066
Less accumulated depreciation		(627,681	)		(551,239	)
Property and Equipment, net	$	324,651		$	370,648

Intangible assets, net

	June 30, 2017			December 31, 2016

Intellectual Property	$	814,582		$	814,582
Patents		191,602			175,047
Less accumulated amortization		(116,839	)		(95,119	)
Intangible assets, net	$	889,345		$	894,510

Amortization expense

The estimated aggregate amortization expense over each of the next five years is as follows:

2017	$	21,798
2018		43,518
2019		43,518
2020		43,518
2021		43,518
Thereafter		557,303
Total Amortization	$	753,172

XML 36 R25.htm IDEA: XBRL DOCUMENT

LOAN PAYABLE (Tables)

6 Months Ended

Jun. 30, 2017

Loan Payable Tables

Loan Payable

Loan payable consist of the following at June 30, 2017 and December 31, 2016:

	2017		2016
Note to a company due September 29, 2017 including interest at 13.25% per annum; unsecured; interest due monthly	$	11,460	$	33,277
Current portion of loan payable		11,460		33,277
Loan payable, less current portion	$	-	$	-

XML 37 R26.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Tables)

6 Months Ended

Jun. 30, 2017

Notes Payable Tables

Notes Payable

Notes payable consist of the following at June 30, 2017 and December 31, 2016:

	2017			2016

Note to a company due August 27, 2017, no interest shall accrue unless and until an event of default occurs, where interest at 10% per annum shall accrue beginning on the date of the applicable event of default, secured by the Company’s intellectual property	$	650,000		$	-
Note to an individual, non-interest bearing, unsecured and has no fixed terms of repayment		50,000			50,000

		700,000			50,000
Unamortized discount		(4,750	)		-
Current portion of loan payable		695,250			50,000
Loan payable, less current portion	$	-		$	-

XML 38 R27.htm IDEA: XBRL DOCUMENT

CONVERTIBLE PROMISSORY NOTES (Tables)

6 Months Ended

Jun. 30, 2017

Convertible Promissory Notes Tables

Convertible promissory

	2017			2016

Convertible promissory notes totaling $700,000 due between November 11, 2017 and December 30, 2017, interest payable at 8% per annum; unsecured; principal and accrued interest convertible into common stock at the lower of $7.00 per share or the price per share of the latest closing of a debt or equity offering by the Company greater than $3,000,000; accrued interest due between November 11, 2017 and December 30, 2017	$	700,000		$	-

		700,000			-
Unamortized discount		(599,063	)		-
Current portion of convertible promissory notes		100,937			-
Convertible promissory notes, less current portion	$	-		$	-

XML 39 R28.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITY (Tables)

6 Months Ended

Jun. 30, 2017

Derivative Liability Tables

Derivative liability

	Level I		Level II		Level III			Total
Cash	$	277,961	$	—	$	—		$	277,961

Derivative liability		—		—	$	(412,777	)	$	(412,777	)

Derivative liability assumptions used

		June 30, 2017
Significant assumptions (weighted-average):
Risk-free interest rate at grant date		1.89%
Expected stock price volatility		79.92%
Expected dividend payout		-
Expected option life (in years)		1
Expected forfeiture rate		0%

Reconciliation of the derivative liability

	June 30, 2017
Value at December 31, 2016	$	-
Initial value at the debt issuance		370,232
Increase in value		42,545
Value at June 30, 2017	$	412,777

- Definition

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41678-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

XML 40 R29.htm IDEA: XBRL DOCUMENT

WARRANT AGREEMENTS (Tables)

6 Months Ended

Jun. 30, 2017

Warrant Agreements Tables

Company stock option activity

The Company’s warrant activity was as follows:

	Warrants		Weighted Average Exercise Price		Weighted Average Contractual Remaining Life
Outstanding, December 31, 2016		4,392,107		1.97		6.17
Granted		1,440,000		2.49		0.75
Exercised		-		-		-
Forfeited/Expired		-		-		-
Outstanding, June 30, 2017		5,832,107		2.10		5.92
Exercisable at June 30, 2017		3,6630,665		2.19		2.95

Range of

Exercise Price

Number of

Warrants

Weighted Average Remaining Contractual Life (years)

Weighted Average Exercise Price

Number of Warrants Exercisable

Weighted Average Exercise Price

$1.00 - $7.00

5,832,107

5.92

2.10

3,630,665

2.19

5,832,107

5.92

2.10

3,630,665

2.19

Weighted Average fair value of warrants granted

	June 30, 2017			December 31, 2016
Significant assumptions (weighted-average):
Risk-free interest rate at grant date		1.89	%		1.83	%
Expected stock price volatility		79.92	%		84.42	%
Expected dividend payout		-			-
Expected option life (in years)		3			3
Expected forfeiture rate		0	%		0	%

XML 41 R30.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2017	May 01, 2017
State of Incorporation	State of Nevada
Date of Incorporation	May 15, 2014
TRDF [Member]
Payment of research project		$ 642,500

XML 42 R31.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Jun. 30, 2017
Manufacturing Equipment [Member] \| Minimum [Member]
Estimated useful lives	5 years
Manufacturing Equipment [Member] \| Maximum [Member]
Estimated useful lives	7 years
Computer and other equipment [Member] \| Minimum [Member]
Estimated useful lives	3 years
Computer and other equipment [Member] \| Maximum [Member]
Estimated useful lives	7 years
Leasehold Improvements [Member]
Estimated useful lives description	Lesser of useful life or the term of the lease

XML 43 R32.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Dec. 31, 2016	Jan. 08, 2016
Summary Of Significant Accounting Policies Details Narrative
Federal deposit insurance corporation	$ 250,000	$ 250,000	$ 250,000
Ownership interest				50.00%
Advertising Expense	68,893	95,226
Valuation allowance percentage			100.00%
Accumulated deficit	(15,880,139)	(15,880,139)	$ (10,718,714)
Working capital deficit	$ 221,888	$ 221,888

XML 44 R33.htm IDEA: XBRL DOCUMENT

INVENTORY (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Inventory Details
Raw Materials	$ 74,678	$ 68,047
Packaging Components	97,782	84,927
Work-In-Process	23,461	17,406
Finished Goods
Inventory, Gross	195,921	170,380
Reserve for Obsolescence	(91,932)	(89,095)
Total inventory	$ 103,989	$ 81,285

XML 45 R34.htm IDEA: XBRL DOCUMENT

PREPAID EXPENSES AND OTHER ASSETS (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Prepaid Expenses And Other Assets Details
Prepaid consulting services	$ 1,011,155	$ 150,168
Prepaid clinical study	642,500
Prepaid insurance	19,270	42,785
Other Receivables	10,178	10,948
Prepaid inventory	6,927	13,178
Prepaid expenses	5,900	6,800
Property and Equipment, net	$ 1,695,930	$ 223,879

XML 46 R35.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Less accumulated depreciation	$ (627,681)	$ (551,239)
Property and Equipment, net	324,651	370,648
Computer and other equipment [Member]
Property and Equipment	147,192	116,747
Leasehold Improvements [Member]
Property and Equipment	36,066	36,066
Manufacturing equipmentt [Member]
Property and Equipment	$ 769,074	$ 769,074

XML 47 R36.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details 1) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Less accumulated amortization	$ (116,839)	$ (95,119)
Intangible assets, net	889,345	894,510
Intellectual Property [Member]
Intellectual Property	814,582	814,582
Patents [Member]
Intellectual Property	$ 191,602	$ 175,047

XML 48 R37.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details 2)	Jun. 30, 2017 USD ($)
Property And Equipment And Intangible Assets Details 2
2017	$ 21,798
2018	43,518
2019	43,518
2020	43,518
2021	43,518
Thereafter	557,303
Total Amortization	$ 753,172

XML 49 R38.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Depreciation expense	$ 37,437	$ 26,507	$ 76,442	$ 54,062
Wrote off intangible					$ 58,522
Amortization expense	10,821	10,667	21,720	21,332
Patents [Member]
Patent costs capitalized	16,555		16,555		45,930
Depreciation on capitalized leased [Member]
Depreciation expense	2,160	$ 2,160	4,320	$ 4,320
Assets Held under Capital Leases [Member]
Capital lease	43,201		43,201		43,201
Accumulated depreciation	$ 32,857		$ 32,857		$ 28,537

XML 50 R39.htm IDEA: XBRL DOCUMENT

LOAN PAYABLE (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Loan payable	$ 11,460	$ 33,277
Loan payable, less current portion
Loans Payable [Member]
Loan payable	11,460	33,277
Current portion of loan payable	11,640	33,277
Loan payable, less current portion

XML 51 R40.htm IDEA: XBRL DOCUMENT

LOAN PAYABLE (Details Narrative) - Loans Payable [Member]	6 Months Ended
	Jun. 30, 2017
Interest rate	13.25%
Maturity date	Sep. 29, 2017

XML 52 R41.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Total notes payable	$ 700,000	$ 50,000
Unamortized discount	(4,750)
Current portion of loan payable	695,250	50,000
Loan payable, less current portion
Individual Counterparty [Member]
Total notes payable	50,000	50,000
Company [Member]
Total notes payable	$ 650,000

XML 53 R42.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Notes Payable Details Narrative
Amortization of discount	$ 5,250	$ 0	$ 5,250	$ 0

XML 54 R43.htm IDEA: XBRL DOCUMENT

CONVERTIBLE PROMISSORY NOTES (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Total Convertible promissory notes	$ 700,000
Unamortized discount	(599,063)
Current portion of convertible promissory notes	100,937
Convertible promissory notes, less current portion
Convertible Promissory Notes [Member]
Total Convertible promissory notes	$ 700,000

XML 55 R44.htm IDEA: XBRL DOCUMENT

CONVERTIBLE PROMISSORY NOTES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Convertible Promissory Notes Details Narrative
Amortization of discount	$ 77,683	$ 0	$ 77,683	$ 0
Accrued interest	3,306	0	3,306	0
Interest expenses	$ 3,306	$ 0	$ 3,306	$ 0

XML 56 R45.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITY (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Cash	$ 277,961	$ 1,106,142	$ 2,025,787	$ 13,352
Derivative liability	(412,777)
Fair Value, Inputs, Level 1 [Member]
Cash	277,961
Derivative liability
Fair Value, Inputs, Level 2 [Member]
Cash
Derivative liability
Fair Value, Inputs, Level 3 [Member]
Cash
Derivative liability	$ (412,777)

XML 57 R46.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITY (Details 1)	6 Months Ended
DERIVATIVE LIABILITY (Details 1)	Jun. 30, 2017
Significant assumptions (weighted-average):
Risk-free interest rate at grant date	1.89%
Expected stock price volatility	79.92%
Expected dividend payout
Expected option life (in years)	1 year
Expected forfeiture rate	0.00%

XML 58 R47.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITY (Details 2)	6 Months Ended
DERIVATIVE LIABILITY (Details 2)	Jun. 30, 2017 USD ($)
Derivative Liability Tables
Value at December 31, 2016
Initial value at the debt issuance	370,232
Increase in value	42,545
Value at June 30, 2017	$ 412,777

XML 59 R48.htm IDEA: XBRL DOCUMENT

WARRANT AGREEMENTS (Details)	6 Months Ended
WARRANT AGREEMENTS (Details)	Jun. 30, 2017 $ / shares shares
Warratns
Outstanding, June 30, 2017 \| shares	5,832,107
Exercisable at June 30, 2017 \| shares	3,630,665
Weighted Average Exercise Price
Outstanding, June 30, 2017 \| $ / shares	$ 2.10
Exercisable at June 30, 2017 \| $ / shares	$ 2.19
Outstanding, December 31, 2016	5 years 11 months 1 day
Warrant [Member]
Warratns
Outstanding, December 31, 2016 \| shares	4,392,107
Granted \| shares	1,440,000
Exercised \| shares
Forfeited/Expired \| shares
Outstanding, June 30, 2017 \| shares	5,832,107
Exercisable at June 30, 2017 \| shares	3,630,665
Weighted Average Exercise Price
Outstanding, December 31, 2016 \| $ / shares	$ 1.97
Granted \| $ / shares	2.49
Exercised \| $ / shares
Forfeited/Expired \| $ / shares
Outstanding, June 30, 2017 \| $ / shares	2.10
Exercisable at June 30, 2017 \| $ / shares	$ 2.19
Outstanding, December 31, 2016	6 years 2 months 1 day
Granted	9 months
Outstanding, June 30, 2017	5 years 11 months 1 day
Exercisable at June 30, 2017	2 years 11 months 1 day

XML 60 R49.htm IDEA: XBRL DOCUMENT

WARRANT AGREEMENTS (Details 1)	6 Months Ended
WARRANT AGREEMENTS (Details 1)	Jun. 30, 2017 $ / shares shares
Number of Warrants \| shares	5,832,107
Weighted Average Remaining Contractual Life (years)	5 years 11 months 1 day
Weighted Average Exercise Price	$ 2.10
Number of Warrants Exercisable \| shares	3,630,665
Weighted Average Exercise Price	$ 2.19
$1.00 - $7.00 [Member]
Range of Exercise Price Lower Limit	1.00
Range of Exercise Price Upper Limited	$ 7.00
Number of Warrants \| shares	5,832,107
Weighted Average Remaining Contractual Life (years)	5 years 11 months 1 day
Weighted Average Exercise Price	$ 2.10
Number of Warrants Exercisable \| shares	3,630,665
Weighted Average Exercise Price	$ 2.19

XML 61 R50.htm IDEA: XBRL DOCUMENT

WARRANT AGREEMENTS (Details 2)	6 Months Ended	12 Months Ended
WARRANT AGREEMENTS (Details 2)	Jun. 30, 2017	Dec. 31, 2016
Significant assumptions (weighted-average):
Risk-free interest rate at grant date	1.89%
Expected stock price volatility	79.92%
Expected dividend payout
Expected option life (in years)	1 year
Expected forfeiture rate	0.00%
Warrant [Member]
Significant assumptions (weighted-average):
Risk-free interest rate at grant date	1.89%	1.83%
Expected stock price volatility	79.92%	84.42%
Expected dividend payout
Expected option life (in years)	3 years	3 years
Expected forfeiture rate	0.00%	0.00%

XML 62 R51.htm IDEA: XBRL DOCUMENT

WARRANT AGREEMENTS (Details Narrative) - License agreement [Member] - USD ($)		2 Months Ended
	Jan. 03, 2017	Jun. 30, 2017
Warrants granted	1,300,000	140,000
Issuance of convertible promissory note		$ 700,000

XML 63 R52.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	Jun. 30, 2017	May 18, 2017	Apr. 24, 2017	Apr. 07, 2017	Dec. 31, 2016
Common stock, par value per share	$ 0.001				$ 0.001
Common stock, shares authorized	75,000,000				75,000,000
Common stock, shares issued	23,751,252				23,336,673
Common Stock, Shares Outstanding	23,751,252				23,336,673
Common Stock [Member]
Common stock, par value per share		$ 2.10	$ 7.00	$ 6.86
Common stock, shares issued		300,000	100,000	14,579
Common share issuances value		$ 630,000	$ 700,000	$ 100,000
Common Stock [Member] \| Prepaid Expenses And Other Assets [Member]
Common share issuances value	$ 76,986
Common Stock [Member] \| Prepaid Expenses And Other Assets One [Member]
Common share issuances value	443,716
Common Stock [Member] \| Prepaid Expenses And Other Assets Two [Member]
Common share issuances value	$ 357,288

XML 64 R53.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Narrative)	3 Months Ended		6 Months Ended
COMMITMENTS AND CONTINGENCIES (Details Narrative)	Jun. 30, 2017 USD ($) ft²	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($) ft²	Jun. 30, 2016 USD ($)
Total rent expense \| $	$ 73,416	$ 72,101	$ 145,815	$ 142,569
Offices And Manufacturing Facility [Member]
Offices and manufacturing facility area	25,000		25,000
Office And Warehouse Space [Member]
Offices and manufacturing facility area	6,547		6,547

XML 65 R54.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] - USD ($)	1 Months Ended
	Jul. 27, 2017	Jul. 19, 2017
Non-refundable fee		$ 35,692
Milestone Payment [Member]
Non-refundable fee		$ 35,692
Individual Counterparty [Member]
Proceeds from convertible promissory note	$ 300,000
Maturity date	Jan. 27, 2018
Interest rate	8.00%
Note conversion description	The conversion price of the Common Stock into which the Principal Amount, or the then outstanding interest due thereon, shall be the lower of $7.00 or the price per share of the latest closing of a debt or equity offering by the Company greater than $3,000,000.
Warrant to purchase common shares	60,000

EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 67 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 66 228 1 false 29 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://makkanotti.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://makkanotti.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://makkanotti.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://makkanotti.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://makkanotti.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS Sheet http://makkanotti.com/role/OrganizationAndDescriptionOfBusiness ORGANIZATION AND DESCRIPTION OF BUSINESS Notes 6 false false R7.htm 00000007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://makkanotti.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 00000008 - Disclosure - INVENTORY Sheet http://makkanotti.com/role/Inventory INVENTORY Notes 8 false false R9.htm 00000009 - Disclosure - PREPAID EXPENSES AND OTHER ASSETS Sheet http://makkanotti.com/role/PrepaidExpensesAndOtherAssets PREPAID EXPENSES AND OTHER ASSETS Notes 9 false false R10.htm 00000010 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS Sheet http://makkanotti.com/role/PropertyAndEquipmentAndIntangibleAssets PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS Notes 10 false false R11.htm 00000011 - Disclosure - LOAN PAYABLE Sheet http://makkanotti.com/role/LoanPayable LOAN PAYABLE Notes 11 false false R12.htm 00000012 - Disclosure - NOTES PAYABLE Notes http://makkanotti.com/role/NotesPayable NOTES PAYABLE Notes 12 false false R13.htm 00000013 - Disclosure - CONVERTIBLE PROMISSORY NOTES Notes http://makkanotti.com/role/ConvertiblePromissoryNotes CONVERTIBLE PROMISSORY NOTES Notes 13 false false R14.htm 00000014 - Disclosure - DERIVATIVE LIABILITY Sheet http://makkanotti.com/role/DerivativeLiability DERIVATIVE LIABILITY Notes 14 false false R15.htm 00000015 - Disclosure - WARRANT AGREEMENTS Sheet http://makkanotti.com/role/WarrantAgreements WARRANT AGREEMENTS Notes 15 false false R16.htm 00000016 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://makkanotti.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 16 false false R17.htm 00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://makkanotti.com/role/Concentration COMMITMENTS AND CONTINGENCIES Notes 17 false false R18.htm 00000018 - Disclosure - LEGAL PROCEEDINGS Sheet http://makkanotti.com/role/LegalProceedings LEGAL PROCEEDINGS Notes 18 false false R19.htm 00000019 - Disclosure - SUBSEQUENT EVENTS Sheet http://makkanotti.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 19 false false R20.htm 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://makkanotti.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 20 false false R21.htm 00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://makkanotti.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://makkanotti.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - INVENTORY (Tables) Sheet http://makkanotti.com/role/InventoryTables INVENTORY (Tables) Tables http://makkanotti.com/role/Inventory 22 false false R23.htm 00000023 - Disclosure - PREPAID EXPENSES AND OTHER ASSETS (Tables) Sheet http://makkanotti.com/role/PrepaidExpensesAndOtherAssetsTables PREPAID EXPENSES AND OTHER ASSETS (Tables) Tables http://makkanotti.com/role/PrepaidExpensesAndOtherAssets 23 false false R24.htm 00000024 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Tables) Sheet http://makkanotti.com/role/PropertyAndEquipmentAndIntangibleAssetsTables PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Tables) Tables http://makkanotti.com/role/PropertyAndEquipmentAndIntangibleAssets 24 false false R25.htm 00000025 - Disclosure - LOAN PAYABLE (Tables) Sheet http://makkanotti.com/role/LoanPayableTables LOAN PAYABLE (Tables) Tables http://makkanotti.com/role/LoanPayable 25 false false R26.htm 00000026 - Disclosure - NOTES PAYABLE (Tables) Notes http://makkanotti.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://makkanotti.com/role/NotesPayable 26 false false R27.htm 00000027 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Tables) Notes http://makkanotti.com/role/ConvertiblePromissoryNotesTables CONVERTIBLE PROMISSORY NOTES (Tables) Tables http://makkanotti.com/role/ConvertiblePromissoryNotes 27 false false R28.htm 00000028 - Disclosure - DERIVATIVE LIABILITY (Tables) Sheet http://makkanotti.com/role/DerivativeLiabilityTables DERIVATIVE LIABILITY (Tables) Tables http://makkanotti.com/role/DerivativeLiability 28 false false R29.htm 00000029 - Disclosure - WARRANT AGREEMENTS (Tables) Sheet http://makkanotti.com/role/WarrantAgreementsTables WARRANT AGREEMENTS (Tables) Tables http://makkanotti.com/role/WarrantAgreements 29 false false R30.htm 00000030 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) Sheet http://makkanotti.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) Details http://makkanotti.com/role/OrganizationAndDescriptionOfBusiness 30 false false R31.htm 00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://makkanotti.com/role/SummaryOfSignificantAccountingPoliciesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://makkanotti.com/role/SummaryOfSignificantAccountingPoliciesTables 31 false false R32.htm 00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://makkanotti.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://makkanotti.com/role/SummaryOfSignificantAccountingPoliciesTables 32 false false R33.htm 00000033 - Disclosure - INVENTORY (Details) Sheet http://makkanotti.com/role/InventoryDetails INVENTORY (Details) Details http://makkanotti.com/role/InventoryTables 33 false false R34.htm 00000034 - Disclosure - PREPAID EXPENSES AND OTHER ASSETS (Details) Sheet http://makkanotti.com/role/PrepaidExpensesAndOtherAssetsDetails PREPAID EXPENSES AND OTHER ASSETS (Details) Details http://makkanotti.com/role/PrepaidExpensesAndOtherAssetsTables 34 false false R35.htm 00000035 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details) Sheet http://makkanotti.com/role/PropertyAndEquipmentAndIntangibleAssetsDetails PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details) Details http://makkanotti.com/role/PropertyAndEquipmentAndIntangibleAssetsTables 35 false false R36.htm 00000036 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details 1) Sheet http://makkanotti.com/role/PropertyAndEquipmentAndIntangibleAssetsDetails1 PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details 1) Details http://makkanotti.com/role/PropertyAndEquipmentAndIntangibleAssetsTables 36 false false R37.htm 00000037 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details 2) Sheet http://makkanotti.com/role/PropertyAndEquipmentAndIntangibleAssetsDetails2 PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details 2) Details http://makkanotti.com/role/PropertyAndEquipmentAndIntangibleAssetsTables 37 false false R38.htm 00000038 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details Narrative) Sheet http://makkanotti.com/role/PropertyAndEquipmentAndIntangibleAssetsDetailsNarrative PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details Narrative) Details http://makkanotti.com/role/PropertyAndEquipmentAndIntangibleAssetsTables 38 false false R39.htm 00000039 - Disclosure - LOAN PAYABLE (Details) Sheet http://makkanotti.com/role/LoanPayableDetails LOAN PAYABLE (Details) Details http://makkanotti.com/role/LoanPayableTables 39 false false R40.htm 00000040 - Disclosure - LOAN PAYABLE (Details Narrative) Sheet http://makkanotti.com/role/LoanPayableDetailsNarrative LOAN PAYABLE (Details Narrative) Details http://makkanotti.com/role/LoanPayableTables 40 false false R41.htm 00000041 - Disclosure - NOTES PAYABLE (Details) Notes http://makkanotti.com/role/NotesPayableDetails NOTES PAYABLE (Details) Details http://makkanotti.com/role/NotesPayableTables 41 false false R42.htm 00000042 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://makkanotti.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://makkanotti.com/role/NotesPayableTables 42 false false R43.htm 00000043 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details) Notes http://makkanotti.com/role/ConvertiblePromissoryNotesDetails CONVERTIBLE PROMISSORY NOTES (Details) Details http://makkanotti.com/role/ConvertiblePromissoryNotesTables 43 false false R44.htm 00000044 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative) Notes http://makkanotti.com/role/ConvertiblePromissoryNotesDetailsNarrative CONVERTIBLE PROMISSORY NOTES (Details Narrative) Details http://makkanotti.com/role/ConvertiblePromissoryNotesTables 44 false false R45.htm 00000045 - Disclosure - DERIVATIVE LIABILITY (Details) Sheet http://makkanotti.com/role/DerivativeLiabilityDetails DERIVATIVE LIABILITY (Details) Details http://makkanotti.com/role/DerivativeLiabilityTables 45 false false R46.htm 00000046 - Disclosure - DERIVATIVE LIABILITY (Details 1) Sheet http://makkanotti.com/role/DerivativeLiabilityDetails1 DERIVATIVE LIABILITY (Details 1) Details http://makkanotti.com/role/DerivativeLiabilityTables 46 false false R47.htm 00000047 - Disclosure - DERIVATIVE LIABILITY (Details 2) Sheet http://makkanotti.com/role/DerivativeLiabilityDetails2 DERIVATIVE LIABILITY (Details 2) Details http://makkanotti.com/role/DerivativeLiabilityTables 47 false false R48.htm 00000048 - Disclosure - WARRANT AGREEMENTS (Details) Sheet http://makkanotti.com/role/WarrantAgreementsDetails WARRANT AGREEMENTS (Details) Details http://makkanotti.com/role/WarrantAgreementsTables 48 false false R49.htm 00000049 - Disclosure - WARRANT AGREEMENTS (Details 1) Sheet http://makkanotti.com/role/WarrantAgreementsDetails1 WARRANT AGREEMENTS (Details 1) Details http://makkanotti.com/role/WarrantAgreementsTables 49 false false R50.htm 00000050 - Disclosure - WARRANT AGREEMENTS (Details 2) Sheet http://makkanotti.com/role/WarrantAgreementsDetails2 WARRANT AGREEMENTS (Details 2) Details http://makkanotti.com/role/WarrantAgreementsTables 50 false false R51.htm 00000051 - Disclosure - WARRANT AGREEMENTS (Details Narrative) Sheet http://makkanotti.com/role/WarrantAgreementsDetailsNarrative WARRANT AGREEMENTS (Details Narrative) Details http://makkanotti.com/role/WarrantAgreementsTables 51 false false R52.htm 00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) Sheet http://makkanotti.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY (Details Narrative) Details http://makkanotti.com/role/StockholdersEquity 52 false false R53.htm 00000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://makkanotti.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://makkanotti.com/role/Concentration 53 false false R54.htm 00000054 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://makkanotti.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://makkanotti.com/role/SubsequentEvents 54 false false All Reports Book All Reports curr-20170630.xml curr-20170630.xsd curr-20170630_cal.xml curr-20170630_def.xml curr-20170630_lab.xml curr-20170630_pre.xml true true ZIP 72 0001477932-17-003933-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-17-003933-xbrl.zip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

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Revenue
Net product sales	$	32,073		$	14,151		$	59,570		$	42,662
Consulting research & development income		-			-			4,448			-
Shipping and other sales		6,812			3,000			6,812			3,098
Total revenues		38,885			17,151			70,830			45,760

Cost of goods sold		39,598			10,579			75,148			37,744
Gross profit (loss)		(713	)		6,572			(4,318	)		8,016
Research and development expenses		205,648			171,447			425,268			298,799
Selling, general and administrative expenses		2,194,950			304,669			4,597,497			596,605
Total costs and expenses		2,400,598			476,116			5,022,765			895,404
Net loss from operations		(2,401,311	)		(469,544	)		(5,027,083	)		(887,388	)

Other income (expense):
Interest income		1			45			5			412
Other income		8,571			8,571			17,142			17,142
Loss on disposal of PP&E		(12,351	)		-			(12,351	)		(3,323	)
Change in derivative liability		(42,545	)		-			(42,545	)		-
Other expense		(6,394	)		(88,491	)		(7,388	)		(100,634	)
Interest expense		(87,054	)		(47,603	)		(89,205	)		(99,321	)
Other income (expense)		(139,772	)		(127,478	)		(134,342	)		(185,724	)
Net loss before income taxes		(2,541,083	)		(597,022	)		(5,161,425	)		(1,073,112	)
Provision for income taxes		-			-			-			-
Net loss	$	(2,541,083	)		(597,022	)	$	(5,161,425	)	$	(1,073,112	)

Net loss per share, basic and diluted	$	(0.11	)		(0.09	)	$	(0.22	)	$	(0.16	)

Weighted average shares outstanding, basic and diluted		23,436,696			6,629,260			23,593,105			6,629,260

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 10, 2017
Document And Entity Information
Entity Registrant Name	CURE PHARMACEUTICAL HOLDING CORP.
Entity Central Index Key	0001643301
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		23,751,252
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2017